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Abstract
The U.S. Food and Drug Administration (FDA) uses the FDA Adverse Event Reporting
System (FAERS) to monitor adverse events resulting from pharmaceutical drug use.
However, this system has limitations such as not allowing real-time data collection. To
address these limitations, the FDA launched the Sentinel Initiative in 2008. This
comparative case study was conducted to describe perceptions of investigating the
efficacy of the Sentinel Initiative compared with the FAERS. The study was based on the
theory of preemption as it emphasized the need for efficient means for providing
unquestionable proof that consumers suffered adverse drug effects. The sample included
interivews of 20 individuals, who worked closely with the FAERS program and were
familiar with the Sentinel Initiative. In-depth key-informant interviews had been
conducted to determine the perceptions of the participants regarding the challenges and
benefits of the Sentinel Initiative compared with FAERS. To analyze data, content
analysis was used. The study concluded that the FAERS and Sentinel Initiative provided
a systematic database, which included health data, that could be used to improve public
health. Due to the FAERS and Sentinel Initiative, adverse effects of drugs will be
recognized and the safety of the patients and the public will be prioritized. The findings
of this study have potential social impact for positive change at the societal level,
organizational level, and individual level in terms of overall safety of the drugs. Sentinel
initiative at its present state complements the existing FAERS and leverage its benefits by
connecting at a grass roots level patients to an organization level as well as stakeholders
to make an impact in providing safer drugs on the market.
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Chapter 1: Introduction
The Institute of Medicine (IOM) identified the mitigation of adverse drug events
(ADEs) and medication errors (MEs) as top national priorities. Budnitz, Lovegrove,
Shehab, and Richards (2012) found that specific drugs had been reported in 88.3% of
emergency hospital admissions of older adults caused by adverse drug events. Identified
drugs tied to emergency hospital admissions were hematologic, endocrine,
cardiovascular, central nervous system, and anti-infective agents (Budnitz et al., 2012).
The findings also revealed that 67% of the hospitalizations were due to unintentional
drug overdoses. In particular, warfarin, insulin, oral antiplatelet agents, and oral
hypoglycemic agents were found to have accounted for 70% the emergency
hospitalizations (Budnitz et al., 2012). According to the Institute for Safe Medication
Practices (2014), when it came to children less than 18 years of age, there were 45,610
Adverse Drug Reactions (ADRs) reported for 2012. Of these, 64% reported suffering a
serious injury. Reports of children experiencing ADRs also increased over time, from
6,320 in 2008 to 11,401 in 2012, increasing at the same rate as for adult patients (Institute
for Safe Medication Practices, 2014).
From 1969 to 2012, the Adverse Events Reporting System (AERS) was the
national database used by the Food and Drug Administration (FDA) to support postmarketing drug surveillance (FDA, 2012a). The FDA moved from the legacy AERS to
the FDA Adverse Event Reporting System (FAERS) in 2012. As a result, AERS and
FAERS were used interchangeably in this study. The referenced sources published before
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2012 might refer the surveillance system as AERS while the referenced sources published
after 2012 might refer it as FAERS, which was the current FDA reporting system.
The MedWatch report was a reporting system used by patients and health care
professionals report problems associated with medicines or medical devices. MedWatch
was very important tool for AERS to obtain safety information on medicinal products
including medical devices. The same reporting form was used for both patients and health
care providers, and the reports could be submitted electronically. The reports obtained
from MedWatch could include information for serious adverse events, product problems,
and medication errors (Craigle, 2007). In 2011, 874,116 reports were received by the
FDA through MedWatch, while only 782,733 out of 874,116 were entered into the
AERS. This was a significant increase from 2003 in which only 370,240 reports were
received by the FDA through MedWatch (FDA, 2012c).
Background
The public saw the FDA as having a big responsibility in ensuring drug safety
(Gavaza et al., 2012). The FDA, however, relies relied on voluntary reporting of adverse
events and potential adverse drug reactions because the FDA has had limited resources to
support active surveillance (Kip et al., 2013). The AERS served as the main surveillance
database used by the FDA used to determine possible safety-related issues of marketed
drugs (Wysowski & Swartz, 2005).
Underreporting, differential reporting, and uneven quality were the common
limitations of the AERS database; nevertheless, the system-generated reports were often
capable of determining serious adverse events to be added to the information on the
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product label (Wysowski & Swartz, 2005). Underreporting referred to only a fraction of
the total number of reportable events being reported (Zhou et al., 2003). Differential
reporting referred to the fact that more serious events were generally reported as well as
the events with shorter onset time, such as vaccinations (Zhou et al., 2003). Lastly,
uneven quality referred to missing or incomplete data on the adverse reaction or reported
event (Wysowski & Swartz, 2005). On rare occasions, additional regulations up to and
including market removal had been required by FDA (Wysowski & Swartz, 2005).
Reports submitted to the FDA reporting system often have insufficient detail
regarding the consumers who experienced the adverse events or medication errors
(Berlin, Glasser, & Ellenberg, 2008; Hochberg, Pearson, O’Hara, & Reisinger, 2009).
The AERS was a system that allowed encoding, managing, analyzing, and reviewing
adverse event reports from either regulated industry professionals or from the public
(Berlin et al., 2008; Hochberg et al., 2009). In response to the limitations of the AERS,
the FDA launched the Sentinel Initiative in 2009, which was designed to provide a
national electronic-based system to monitor the safety of medical products, including
drugs, biologics, and medical devices following the mandate of Congress in the FDA
Amendments Act of 2007 (Platt et al., 2012). The Sentinel Initiative includes two
components, which were Mini-Sentinel Initiative and the federal partner collaborations
(Racoosin, Robb, Sherman, & Woodcock, 2012).
The Mini-Sentinel Initiative, as a part of the pilot phase of the Sentinel Initiative,
was an electronic program that involved the participation of many different data partners,
wherein each data partner hosted electronic health care information about the medication
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people took and their clinical diagnoses. When the FDA had a query for report
generation, each data partner would run the exact same query to generate aggregate
reports to be sent back to the FDA (Racoosin et al., 2012). To facilitate this process, all
data partners had a common data model. The second component of the Sentinel Initiative
was federal partner collaboration among the Center for Medicare and Medicaid Services,
the Veterans Administration, and the Department of Defense. These federal partners
administered or ran a population specific health care system (Racoosin et al., 2012).
Given the limitations of AERS, including the application of the Sentinel program, the
FDA moved from the legacy AERS to the FDA Adverse Event Reporting System
(FAERS) in 2012. FAERS contained data encoded into the system since 2004. The data
were presented at the individual report level with potential duplicates due to factors such
as follow-up reports on a case.
There was a need to assess the benefits and challenges of surveillance
methodology associated with the FDA’s Sentinel Initiative compared to FAERS. The aim
was to conduct a comparative case study of the current FAERS surveillance system and
the FDA's Sentinel Initiative to determine the impacts and benefits of the Sentinel
Initiative in terms of consumer safety. A summary of the attributes of the FAERS and the
Sentinel Initiative is presented in Table 1.
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Table 1
FAERS and Sentinel Descriptions
FAERS
To report the adverse effects of
drugs and to provide a
database for these reported
cases of adverse drug reactions

Sentinel
To develop and implement a
proactive system that would
complement existing systems
that the agency had in place to
track reports of adverse events
linked to the use of its regulated
products

Size/Capacity

Depend on information
reported by consumers, Health
Care Professionals etc.

Utilized existent large number
of databases containing safety
information

Activities

Report generation regarding
errors in medication.
Information storage on adverse
events

Query diverse automated health
care data holders to evaluate
possible medical product safety
issues quickly and securely

Function/Purpose

Support for FDA’s postmarketing safety surveillance
program for drug and
therapeutic biologic products
Limitations

There was no certainty that the
reported event was actually
due to the product (FDA did
not require a causal
relationship between a product
and event).
The quality of reporting was
dependent on the quality of the
reports.
Reports did not always contain
enough detail to properly
evaluate an event. FDA did not
receive reports for every
adverse events

There were some data that might
be missing in the database to
facilitate activities other than
analysis of errors in medication
(e.g., filing of claims).
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Problem Statement
The current FDA consumer safety surveillance system used FAERS for the
reporting of adverse events involving pharmaceutical drugs (FDA, 2012a; Powers &
Cook, 2012;). The FAERS used a database that was designed to assist the FDA and its
partners to monitor postmarketing safety of approved drugs and other biologic products
(Powers & Cook, 2012). The FAERS had limitations including not allowing real time
data collection (FDA, 2012a). In response to these limitations, the FDA launched the
Sentinel Initiative in 2008. However, there is a dearth of literature regarding the impact of
Sentinel Initiative compared to the FAERS. There is a need to assess the benefits and
challenges associated with the FDA’s Sentinel Initiative compared to the current FAERS
surveillance methodology.
This comparative case study was conducted to assess the impact of two systems:
the Sentinel Initiative and FAERS. According to the FDA (2012a), the FAERS had two
functions: (a) a system for reporting the adverse effects of drugs, and (b) a database for
these reported cases of ADRs (FDA, 2012a). As for the Sentinel Initiative, the function
was to build and implement a national electronic system for monitoring the safety of
FDA-approved drugs and other medical products (FDA, 2012d).
The FAERS and the Sentinel program were both ADR reporting systems. The
Sentinel system was developed and implemented as an aid to the existing FAERS. The
FAERS did not make use of data at the point of care, which referred to the precise time or
location that a drug was used or consumed by the market members (Gottlieb, 2005).
According to the FDA (2012b), “The Sentinel System enables FDA to actively query
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diverse automated healthcare data holders—like electronic health record systems,
administrative and insurance claims databases, and registries—to evaluate possible
medical product safety issues quickly and securely” (para. 2).
Purpose of the Study
The purpose of the comparative case study of the FAERS surveillance system and
the FDA’s Sentinel Initiative was to determine the benefits and consequences of the
Sentinel Initiative in terms of drug consumer safety. This qualitative study focused on the
perceptions of individuals who had worked closely with FAERS program and were aware
of the Sentinel Initiative. Key informants were interviewed who worked with FAERS
andwere familiar with the Sentinel Initiative to understand their perceptions of the
differences between these two programs.
Currently, the reporting system utilized by the FAERS is voluntary and quarterly
(Powers & Cook, 2012). Instead of depending on point of care data collection, Sentinel
Initiative could access multiple existing data systems such as electronic health record
systems and medical claims databases (Platt et al., 2009). No quantification of data was
carried out to compare information on the two programs. Instead, the perceptions of key
informants were used to describe any differences between the two programs.
Research Questions
In conducting a comparative case study on the perceptions of the two systems that
the FDA used to detect ADRs, these following research questions were used:
Research Question 1: What are the prospective benefits of the FDA’s Sentinel
Initiative as compared with the FAERS surveillance methodology?
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Research Question 2: What are the challenges and negative impacts of the FDA’s
Sentinel Initiative as compared with the FAERS surveillance methodology?
Research Question 3: What are the lessons learned that can enhance the scope of
the Sentinel Initiative?
Theoretical Framework
The theory of preemption was used to frame the study. The theory of preemption
assumes the importance of using information to make sound judgments regarding issues
or activities of national importance, such as prescription drug-related regulations or
required uniform federal regulation, which cannot be provided by states (Deftos, 2008;
Glantz & Annas, 2008). The theory of preemption is used to analyze data from ADRs and
cases to address the damages experienced by affected consumers (Valoir & Ghosh,
2011).
The theory of preemption might shield drug manufacturers from certain liabilities
when consumers experience adverse effects from their products (Curtin & Relkin, 2007).
Court rulings and federal decisions had shown support for the protection of drug
manufacturers who faced allegations of adverse drug effects from their consumers
(Curtin & Relkin, 2007). Preemption prevented state courts from assessing the safety and
efficacy of a drug when it came to a personal injury products liability lawsuit, thereby
giving drug manufacturers the ability to avoid litigation even if the patient who suffered
from ADR had already filed a complaint against the company to the FDA (Shniderman,
n.d.).
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The theory of preemption was important in framing the study as it emphasized the
need for efficient means for providing unquestionable proof that consumers suffered
adverse drug effects. Because this studyfocused on the comparison between two
surveillance and reporting systems with the goal of improving drug safety, the theory of
preemption was the most appropriate theoretical framework for the study. Under the
theory, the FDA required current, accurate, and actionable information to ensure
consumer safety, especially in detecting uncommon cases of product exposures (Platt et
al., 2009).
Nature of the Study
This comparative case study design waswas qualitative in nature. Qualitative
methodology was appropriate for this study because qualitative studies are used to
explore a phenomenon within its natural environment (Yin, 2011). Moreover, a
comparative case study design was appropriate because the aim was to explore the
differences and similarities between two cases, (a) use of FAERS and (b) use of Sentinel
Initiative, based on the perspectives of participants (Yin, 2011). In-depth key-informant
interviews had been conducted to determine the perceptions of the participants regarding
the challenges and benefits of the Sentinel Initiative compared with FAERS. The data
analysis technique used was content analysis. Krippendorff (2004) stated that content
analysis involved the development of thematic categories and themes from qualitative
data. Open coding was used to analyze the data to extract the key themes related to the
research questions.
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Key informants included drug company safety professionals who had selfreported knowledge or expertise in assessing consumer impact. The participants were
selected from various departments within pharmaceutical companies located in the
United States. The participants were subject matter experts in the field of
pharmacovigilance. Sampling involved participants at different levels from different
therapeutic departments such as pain and inflammation, cardiovascular, and psychiatric
and mental health.
Definitions
Adverse drug reaction (ADR): “Any response to a drug, which is noxious,
unintended and occurs at doses normally used for prophylaxis, diagnosis or therapy” (van
Grootheest & Richesson, 2012, p. 368).
Pharmacovigilance: “The science and activities relating to the detection,
assessment, understanding and prevention of adverse effects or any other drug-related
problems” (World Health Organization [WHO], 2014, para. 1).
FDA Adverse Event Reporting System (FAERS): An information database system
which was acted as the post-market monitoring system for the FDA. FAERS used
historical data or information to supervise new adverse events and medication errors from
drug and therapeutic biologic products (FAERS, 2012a).
FDA Sentinel Initiative: A national electronic system that allowed the FDA to
comprehend and ensure the safety of specific medical products (FDA, 2012b).
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Assumptions
There were several assumptions in the study. The first was that the participants
would answer each question in the interview as truthfully and accurately as possible. This
was a necessary assumption because this could not be controlled fully; however, before
the interview started, the participants were reminded of this. The second assumption was
that the two programs were comparable, especially because they dealt with the same
issues, specifically adverse event reporting. The third assumption was that the both
programs had benefits and challenges to determine room for improvement as part of the
implications of the study findings.
Scope and Delimitations
The perceptions of the participants were gathered regarding the challenges and
benefits of the Sentinel Initiative compared with the FAERS. Interviews were conducted
with participants who met the inclusion criteria: (a) safety professionals from drug
companies and (b) had self-reported knowledge or expertise in assessing consumer
impact.
Limitations
There were many limitations in this study such as sample size, researcher bias,
and data collection bias. Each limitation had an impact on this study and every effort was
made to control the effects of the limitations. One limitation was researcher bias. I have
extensive knowledge of Adverse Drug Reactions (ADRs) and pharmacovigilance
systems. To mitigate this bias, data collected was examined during participant interviews
as is and conducted member checks to ensure that the interpretations made were
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consistent with the actual interpretations intended by the participants. This limitation
might have had an effect on the interview questions used for data collection. Recognizing
this, the questions were written without bias to allow the participants to use their
experiences and knowledge to answer the questions.
Another limitation was the possibility of not obtaining enough participants. Key
informants included drug company safety professionals who had self-reported knowledge
or expertise in assessing consumer impact. Another factor that might have resulted in
inadequate results was poorly developed interview questions. The interview guide must
be developed properly to be open ended yet specific enough to avoid confusion. To avoid
this pitfall, proper considerations were given in developing the interview guide. Another
limitation was sample size selection. The study was limited to sample 20 participants
with the consideration of data saturation. The required sample size for qualitative studies
was based on the point of data saturation (Mason, 2010).
Social Significance
This study definitely may have potential to increase awareness of advantages and
disadvantages of the FAERS and the Sentinel Initiative programs. It was expected that
the data would provide information regarding the effectiveness of the FAERS and the
Sentinel Initiative. This study may increase public knowledge of the reporting systems
used by the FDA to control ADRs. The lessons learned from this study may be used to
support the FDA’s efforts to improve reporting systems’ effectiveness to detect ADRs.
This current study may also add to the research base regarding pharmacovigilance
systems. Moreover, with the findings of the study, the benefits and challenges of the
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FAERS and the Sentinel systems may serve as basis for further improvements to the
programs. As a result, health and quality of life may be improved because the challenges
of the programs on ADR generation may be identified for ease of addressing them. It
could support the FDA’s efforts to improve reporting systems effectiveness to detect
ADRs.
Summary
The occurrence of ADRs in the United States had increased in the past decade
(Yadav, 2009). ADRs were costly and could have a negative impact on public health
programs that detect ADRs (Yadav, 2009). Furthermore, ADRs were among the leading
causes of death in many countries, including the United States. According to Keating and
Millman (2014), from 2004 to 2012 men and women reported 60,000 deaths. Despite the
similarities in their numbers, death was the number one ADR among men, while it was
the ninth among women. Pharmacovigilance systems were used to detect and prevent
ADRs. The purpose of this qualitative comparative case study was to compare two ADR
reporting systems to determine whether one was more effective than the other. This
investigation might lead to a better understanding of the effectiveness of the ADR
reporting systems and assist the FDA with improving ADR surveillance and reporting.
The next chapter presents a detailed review of related literature.
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Chapter 2: Literature Review
The purpose of this comparative case study of the US Food and Drug
Administration (FDA) Adverse Events Reporting System (FAERS) surveillance system
and the FDA’s Sentinel Initiative was to determine the benefits and consequences of the
Sentinel Initiative in terms of drug consumer’s safety. Instead of depending on point-ofcare data collection like the FAERS surveillance system, the Sentinel Initiative accessed
multiple existing data systems, such as electronic health record systems and medical
claims databases (Platt et al., 2012). Perceptions of the perceived challenges and benefits
of FAERS and Sentinel Initiative were gathered through key informant interviews with
individuals who worked with FAERS and were familiar with the Sentinel Initiative. Robb
et al. (2012) described the mission of the FDA as providing health protection to the
public. To do this, the regulatory body ensured the safety, efficacy, and quality of the
human drugs. Aside from human drugs, the FDA also regulated the quality and safety of
biologic products, medical devices, and more (Robb et al., 2012).
For years, the regulating body was dependent mostly on spontaneous reporting
systems to complete its task of monitoring post-market safety. The FDA relied heavily on
the public, practitioners, and consumers to voluntarily report adverse drug effects, errors,
and other quality problems either to the FDA or directly to the drug companies. Although
manufacturers were mandated by law to report to the FDA when adverse events were
reported to them, the FDA still required active public participation in reporting such
occurrences. Naturally, these spontaneous reporting approaches for ADRs had their
limitations (Robb et al., 2012).
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One of the weaknesses of such an approach was the underreporting of adverse
events and incomplete information on the reports submitted to the FDA. Moreover, even
though these systems were strong for developing hypotheses regarding possible productassociated adverse events, the number of events being reported did not accurately
represent the actual number of cases of ADRs (Alvarez-Requejo et al., 1998).
Aggravating this was the lack of exposure data, which served as a barrier for accurately
calculating adverse event rates. The FDA was aware of these limitations and continued to
strive for stronger post-market safety monitoring. The literature review begins with the
history of the FDA and its role in ensuring drug safety, followed by studies covering
ADR surveillance using FAERS and the Sentinel Initiative.
Literature Search
To conduct the literature review, relevant studies were searched that contributed
to the development of the research topic for this study. The databases used for this study
were EBSCOHost, PsychArticles, ProQuest, and ScienceDirect. The key words used
included adverse events reporting system, surveillance system, FAERS, FDA Sentinel
Initiative, pharmacovigilance, and ADR. The search for articles was focused on works
published from 2009 to 2014, with exceptions for seminal works that were essential to
the development of the study. The key words were used in the database search as
individual and combined terms to identify appropriate articles for this literature review.
Theoretical Framework
The theory used to frame this study was the theory of preemption, which is based
on the supremacy clause of the U.S. Constitution and can be applied to state statutes,
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regulations, or common-law damage actions. When it comes to preempting common-law
damage actions, the plaintiffs cannot sue for damages regarding injuries caused by a
product. Preemption is considered an affirmative action, which means the burden of proof
lies with the defendant to adhere to the preemptive effect of the federal law (Shniderman,
n.d).
Because the theory of preemption involves the use of data to make market-based
decisions regarding drug safety (Gostin, 2011), the theory of preemption was the most
appropriate theoretical framework for the study, which focused on the comparison
between two surveillance and reporting systems with the goal of improving drug safety.
The theory of preemption is used with quantitative data from adverse drug effect reports
and cases to address the damages experienced by affected consumers (Gostin, 2011).
According to Gostin (2011), the two cornerstones of the preemption theory are
Congress’s intent to be the ultimate touchstone and the “strong presumption against
preemption when the state exercises its historic police powers” (p. 11). Because of this
doctrine, even though the FDA was viewed as ineffective and even if ineffective drugs
and devices were being marketed, consumers had limited recourse to be fairly
compensated for their injuries (Gostin, 2011).
The theory of preemption shields drug manufacturers from certain liabilities when
consumers experience adverse effects from their products (Shniderman, n.d.). Preemption
is often the position taken when an injury to a patient or plaintiff is reportedly caused by
prescription drugs (Shniderman, n.d.). Under this theory, the approval process is the
focus and not the post-approval sales. For the FDA, product liability lawsuits can threaten
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the agency’s capabilities in regulating risk information for prescription drugs. Under
preemption, the FDA is considered to have the requisite expertise to deal with issues of
safety and efficacy of prescription drugs. The FDA argued that approval of drugs’ label
demonstrated the agency’s definitive judgment of certain risks and this judgment should
be protected from second-guessing (Kessler & Vladeck, 2008). Recent court rulings and
federal decisions had shown much support for the protection of drug manufacturing
companies who faced allegations of adverse drug effects from their consumers (Curtin &
Relkin, 2007). This theory was important in framing and shaping the significance of this
study as it emphasized the need for efficient means of providing unquestionable proof
that consumers suffer adverse drug effects.
Evolution of FDA and Drug Safety
History of Drug Safety
Ensuring the safety of the food supply and safeguarding the public from the
practice and effects of adulteration and misleading marketing was probably the earliest
regulatory task undertaken by ancient governments, and when the Roman civil law was
established, there were already complex rules addressing these issues (Borchers, Hagie,
Keen, & Gershwin, 2007). In the United States, such regulatory activities were originally
under the auspices of the state. No federal food laws were designed until the 1880s, when
Congress started to enact statutes regulating individual food items, such as the laws
banning the importation of adulterated tea, limiting the manufacture of oleomargarine,
and inspecting meat produced for exportation (Borchers et al., 2007).
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The history of federal drug laws could be observed to go back further. In 1813,
Congress put into place the Vaccine Act, which was the first statute facilitating the
regulation of adulterated drugs. Afterward, a more general federal law on drug
adulteration was called for. The U.S. -Mexican war had just ended, and members of
Congress were convinced that adulterated and decayed foods and drugs explained why
there was a high mortality of soldiers in this war (Borchers et al., 2007). Although many
soldiers of the U.S.- -Mexican war died because of the infectious diseases and general
inadequacy of medical treatment, Congress was convinced that adulterated and inferior
drugs played a large role in the high mortality rate of the soldiers, and this conviction led
to the passage of the Drug Importation Act of 1848. The Treasury Department acquired
the responsibility of enforcement but found it difficult over time. In addition, one
weakness of the law was that it only addressed the importation of adulterated drugs and
not their manufacture and sale within the United States (Borchers et al., 2007).
The Division of Chemistry investigations began in the mid18th century, and
Wiley, who became chief chemist in 1883, greatly influenced the U.S. government to
take on the adulteration and misbranding of foods and drugs. Wiley published a 10-part
study in 1887 called “Foods and Food Adulterants,” and in 1902 conducted famous
poison squad experiments in which volunteers would take food additives to see their
reaction (Borchers et al., 2007). Wiley then convinced the General Federation of
Women’s Clubs, consumer groups, trade associations, professional groups, and state food
and drug officials to stand behind a federal law prohibiting adulteration and misbranding
of foods and drugs (Borchers et al., 2007).
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Role of FDA in Drug Safety
When the 19th Century ended, many infectious diseases were discovered.
Antitoxins and vaccines could treat and prevent the diseases. However, in October and
November 1901, 13 children died because of inoculation with a diphtheria antitoxin
contaminated with tetanus bacillus (Borchers et al., 2007). As an immediate response,
Congress and President Theodore Roosevelt passed the Biologics Control Act of 1902
mandating that establishments wanting to produce and sell market vaccines and
antitoxins should have the required licenses. This was facilitated by the Public Health and
Marine Hospital Service, now known as the U.S. Public Health Service (Borchers et al.,
2007).
The Wiley Act, or the Pure Food and Drugs Act of 1906, banned interstate
commerce in adulterated foods, drinks, and drugs. The Act mandated that producers
should put labels on their products that indicated whether the medication consisted of
“alcohol, opium, cocaine, morphine, chloroform, marijuana, acetanilide, chloral hydrate,
and in what amount” (Borchers et al., 2007, p. 6). However, while the Wiley Act
prohibited false and misleading statements on the product or its ingredients, the Act did
not consider advertising material as part of the label. This created vagueness of the Act.
Nevertheless, the Act was commended for establishing the role of the federal government
as the protector of consumers. Moreover, the Wiley Act created the first federal
regulatory agency that would later become the FDA. Wiley, who was the head of the
Bureau of Chemistry, took on the role of the first chief administrator of this new agency
(Borchers et al., 2007). The Wiley Act, however, was complex to enforce partly because
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there was insufficient budget and partly because the Bureau of Chemistry had to bring
each company to court to prove adulteration, mislabeling, or other violations. While the
Act put forward what was fraudulent (misleading the consumer), it was not easy to prove
fraudulence took place (Borchers et al., 2007).
The FDA petitioned for changes in laws, which “legally mandated quality and
identity standards for foods, the prohibition of false therapeutic claims for drugs,
coverage of cosmetics and medical devices, clarification of the FDA’s right to conduct
factory inspections and control of product advertising, among other items” (Hickmann,
2003, p. 11). Together, the FDA and a new generation of journalists and consumer
organizations banded together in attempts to influence the passing of this new legislation
through a reluctant Congress (Hickmann, 2003, p. 11). Unfortunately, it was another
therapeutic disaster that propelled the legislation through Congress, for in 1937, a
Tennessee drug company marketed elixir sulfanilamide, which was popular in the
pediatric population. This sulfa drug contained a chemical found in antifreeze; as a result
of the substance, more than 100 people died, most of them were children (Hickmann,
2003, p. 183).
Because of the Tennessee drug company tragedy, Congress enacted the Food,
Drug, and Cosmetic Act on June 25, 1938. This Act regulated cosmetic and medical
device and requirement of label medication with usage instructions. In addition, premarket approval from the FDA was another big initiative that enhanced safety and
efficacy of drugs. Another positive change resulted in the area of food packages, food
quality, and its standards. This law authorized the FDA to inspect factory facilities and
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enforce other safety requirements per the agency’s guidelines (FDA, 2012d). In addition,
in 1938, another therapeutic disaster spawned the creation of the Kefauver-Harris
Amendments. Thalidomide, a sedative that was used outside of the United States, had
caused thousands of deformed newborns. The Kefauver-Harris Amendments also
provided for drug efficacy and safety evaluation by the FDA before marketing, stricter
regulation of drug trials, improved drug manufacturing practices, and the empowerment
of the FDA to assess drug company production and control records (FDA, 2009).
In 1960, more than $1 billion dollars of medical devices were shipped by more
than 1,000 manufacturers. In the early 1970s, approximately 10,000 injuries were
documented by government because of usage of these medical devices. However, after
causing more than 200-second trimester septic abortions and 11 maternal deaths, the
Dalkon Shield intrauterine device was withdrawn from the market. In response to this and
other events, Congress enacted the Medical Amendments of 1976 to ensure the FDA’s
ability to maintain safety and effectiveness of medical devices entering the market
(Maisel, 2004). The legislation was founded on the idea that the degree of device
regulation should correspond to the degree of risk one could be exposed to by using the
device. As a result, the FDA pre-market evaluation and approval, carried out by the
Center for Devices and Radiologic Health, was largely determined by what the device
was and the level of risk perceived to the patient’s health (Maisel, 2004).
The legislation included three regulatory classes. This new legislation divided
medical devices into three tiers based on the risk posed by the device. Class 1 (low risk
devices) medical devices operated under FDA general controls and included products
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such as stethoscopes and tongue blades. Because they posed minimal risk, their safety
and effectiveness were maintained through general controls only (Maisel, 2004). Class 2
(moderate risk devices) medical devices functioned under FDA performance standards
and consisted of such products as computed tomography scanners and gastroenterology
endoscopes. Class 2 devices were regulated by making sure they met or even exceeded
specific predefined product performance standards (Maisel, 2004). Class 3 devices
(higher risk devices) such as pacemakers and silicone breast implants were the most
heavily regulated and require the FDA’s premarket approval (Maisel, 2004). The safety
and effectiveness of Class 3 devices were maintained by carrying out a comprehensive
and thorough pre-market evaluation and approval process (Maisel, 2004).
According to Maisel (2004), for devices to be stamped with FDA approval and
enter the United States market, manufacturers should first show that the device was safe
by proving the possible risks were minimal or the benefits would outweigh the risks.
Manufacturers should also show that the device was effective by proving that it could do
what it committed to do for users. Manufacturers must show data that supports their
safety and effectiveness claims, which might include verification and validation studies,
observational studies, randomized clinical trials, manufacturing tests, and statistical risk
analyses (Maisel, 2004). The manufacturer would choose evidence based on what was
required by the FDA to determine safety and effectiveness, which was largely dependent
on the type of device and what it had promised to users. The perceived risk of the user’s
well-being was also a factor determining what evidence the FDA would ask for. For
example, if a device was manufactured with the intention of treating a life-threatening
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condition for which no alternative existed, the FDA might consider the device as having a
higher acceptable risk compared to devices that were manufactured with the intention of
treating a benign condition (Maisel, 2004). Congress called for the FDA to use the “least
burdensome approach,” which meant the FDA should only require manufacturers to
provide the necessary data for them to prove the safety and effectiveness of their devices
(Maisel, 2004).
Under this new regulation, devices were approved by the FDA and entered the
market in either of the two ways: first, by showing substantial equivalence to an already
approved and legally marketed device and second, by providing data as evidence of
safety and effectiveness through the Pre-market Approval Application (Maisel, 2004).
Devices that posed only minimal risk were exempted from intense scrutiny and might
only need to be subjected to registration and listing with the FDA. Others might only
require evidence that they had passed compliance with manufacturing guidelines. The
FDA put forward Guidance documents, which summarized what manufacturers need to
provide and show before their devices were approved (Maisel, 2004). According to
Borchers et al. (2007), the evolution of FDA could be characterized as a series of “crisislegislation-adaptation cycles.” It was always a crisis that triggered a legislation to be
made and followed by the implementation or adoption of the FDA legislation.
Pharmacovigilance
Pharmacovigilance referred to science and activities linked to detection,
assessment, understanding and prevention of adverse effects or any other drug-related
problem (WHO, n.d.). Pharmacovigilance activities encompassed the collecting,
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exchanging, accumulating, analyzing, interpretation and sharing of data regarding the
experiences of patients who had used a specific drug or certain therapeutic agent.
Pharmacovigilance played an important role in ensuring drug safety and the activities
associated with it had become increasingly scrutinized by the drug industry (van
Grootheest & Richesson, 2012, p. 368). According to van Grootheest and Richesson
(2012), pharmacovigilance and drug safety monitoring activities could shape clinical
research practices significantly. Most pharmacovigilance and population monitoring
activities were also clinical research studies themselves, so that they could also affect
research and development activities. The findings of pharmacovigilance and drug safety
monitoring activities could led to improved decisions by treatment agent manufacturers
as well as improved future trials (van Grootheest & Richesson, 2012).
If there were no systematic detection and assessment practices in place that could
deal with adverse drug effects, thousands of individuals might suffer from side effects of
the drugs they used before a clinician could be subjected to public investigation and
action (van Grootheest & Richesson, 2012). An adverse event was a clinical event, sign
or symptom that deviated from the wanted results. No concept of causality had been
asserted with adverse events. On the other hand, an ADR implied causality or a causal
relationship between the drug and the event. One was the probable cause and one was the
effect. If an ADR were suspected, then trials and tests would have to be carried out in
order to confirm or refute the suspicion. Before tests were carried out, careful and
systematic collection of data was necessary (van Grootheest & Richesson, 2012).
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The decision to ban thalidomide from the market was the result of actively
collecting data and cases of adverse reactions to the drug. This case also propelled the
FDA to start a systematic collection of ADR reports, mainly through the Hospital
Reporting Program. The case also led to different countries establishing policies that
would regulate new drugs, which composed of new rules and regulations that new drugs
have to meet before receiving marketing authorization. Moreover, marketing
authorization holders were commissioned to form a system focused on post-marketing
surveillance so that ADRs could be detected as early as possible and prevented a similar
case as the thalidomide from taking place (van Grootheest & Richesson, 2012). In 1968,
10 countries that supported the spontaneous reporting system of ADRs collaborated to
establish International Drug Monitoring (Lindquist, 2003). In 1971, the 20th World
Health Assembly proposed the foundations for the WHO International Drug Monitoring
programme (van Grootheest & Richesson, 2012). In 1972, a report was written to serve
as the foundation for the international system of national centers working together under
the WHO programme (van Grootheest & Richesson, 2012).
Even though these sophisticated programs and models had changed through time,
the motivation and main strategies behind pharmacovigilance had not changed. The main
motivation to carry out pharmacovigilance was still to ensure public safety and the main
strategy was still population monitoring (van Grootheest & Richesson, 2012). In addition,
the overall goal of pharmacovigilance was to balance the risks associated with a drug to
the benefits that could be gained from it. Pharmacovigilance sought to balance the riskbenefit ratio of drugs for the public. It perceived that all therapeutic agents had a specific
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level of risks and these risks were not equally distributed across the population. Some
groups were more likely to suffer from ADRs compared to others (van Grootheest &
Richesson, 2012). Pharmacovigilance did not deny the possibility of risks associated with
certain drugs and more importantly; it was cognizant that individual variations that could
affect the course of a disease should be taken into consideration. Individual variations
also dictated the preferences of treatment options and an individual’s tolerance of side
effects (van Grootheest & Richesson, 2012).
According to Raine (2012), harmful effects from drugs should be monitored, as
they could be deadly and costly to the healthcare sector. The costs were high in
developed countries, but could be even greater in developing countries (Raine, 2012). For
these countries, even if only a few patients suffer real harm from ADR, these incidents
might cause significantly negative consequences on the credibility and success of
important public health programs (Raine, 2012).
Such situations highlighted the need for pharmacovigilance, which was the
science and method of detection, assessment, and comprehension of adverse drug related
problems. To enhance pharmacovigilance strategies, the WHO claimed that more
emphasis must be given to the planning and implementing of ADR surveillance systems
(Raine, 2012).
Methods in Pharmacovigilance
There were various methods used in detecting new ADR, categorized into premarketing and post-marketing studies. The primary method of gathering information
regarding a drug before it was marketed was the carrying out of a clinical trial (van
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Grootheest & Richesson, 2012). Double-blind randomized controlled trials comprised the
most comprehensive method of determining the possible cause-effect relationship
between a treatment agent and a specific outcome. This study was not completely
effective in determining the safety of a drug, especially because only limited number of
patients participates. This made it impossible to determine rare ADRs as a result.
Moreover, the short period on which clinical trials were carried out made it challenging
to identify ADRs with a long latency (van Grootheest & Richesson, 2012). The
effectiveness of clinical trials was also questionable when the population in which a drug
was tested was taken into account (van Grootheest & Richesson, 2012).
Specifically, the problem lied with the fact that characteristics of the persons to
which this drug was tested would not always correspond to the characteristics of the
people who would actually use the drug. This made it harder to generalize findings
gathered from clinical trials to the population at large. This could be especially observed
among the elderly, women and with disabilities (van Grootheest & Richesson, 2012).
Rare ADRs therefore could be detected more with post-marketing studies rather that tests
carried out before the drugs were carried out. Careful monitoring of the drug and its
effects after they had been released to the market was necessary (van Grootheest &
Richesson, 2012).
Post-marketing studies could be either descriptive or analytical (van Grootheest &
Richesson, 2012). The former type of post-marketing studies could lead to hypotheses
that would describe how events occurred in relation to the toxicity of the drug as well as
its effectiveness. Causal relations therefore could be depicted through this. Under post-
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marketing surveillance, the hypotheses generated from the descriptive studies served as
the starting points of analytical studies (van Grootheest & Richesson, 2012). Spontaneous
reporting as well as intensive monitoring were the two dominant types of descriptive
studies. On the other hand, there were different methods to carry out analytical studies
such as case-control studies, cohort studies, clinical trials and more others. Most of these
studies could only be carried out if there were already reliable data available (van
Grootheest & Richesson, 2012).
A spontaneous reporting system (SRS) such as FAERS was considered the main
method of gathering post-marketing information regarding the safety of drugs. SRS were
designed to detect signals of new, rare, as well as significant ADRs as early as possible.
By having an organized spontaneous reporting system, parents, physicians, and the
patients would all have the opportunity to reported ADRs as early as the day they had
suspicions to a pharmacovigilance center (van Grootheest & Richesson, 2012).
The pharmaceutical companies also made use of SRS to research their own drugs.
The SRS enabled them to monitor their drugs at their whole life cycles for minimal costs
(van Grootheest & Richesson, 2012). However, SRS were critiqued for their selective
and underreporting. According to a study, where the researchers evaluated the magnitude
of underreporting, more than 94% of ADRs were not being reported. Because of this
underreporting, FDA, the pharmaceutical companies, and the public had a misconception
that the specific drug was safe. On the other hand, selected reporting of risks could lead
to the misconception that a specific risk existed when there was none (van Grootheest &
Richesson, 2012).
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Still, even though criticisms abound, it had proven its value throughout the years.
From 1999 to 2011, 11 drugs were withdrawn from the American and British markets,
which were two of the globally prominent markets. This showed how valuable SRS was.
Among the 11 drugs, eight were removed because of the findings shaped by and because
of spontaneous reporting (van Grootheest & Richesson, 2012). The WHO gave
importance to spontaneous reporting systems as an important part of pharmacovigilance,
given their capacity to reduce the risk of drug-related problems (Raine, 2007). According
to Herdeiro et al. (2012), spontaneous report methods were the most dominant form of
reporting ADRs. However, this method was prone to physicians’ underreporting
(Herdeiro et al., 2012).
To address this concern, Herdeiro et al. (2012) conducted an experiment to see if
particular interventions could help increase instances of physicians reporting ADRs.
Herdeiro et al. (2012) compared the results of workshops and over-the-phone interview
interventions designed to enhance the quantity and relevance of ADR reporting by
physicians. Herdeiro et al. (2012) performed a cluster-randomized controlled trial,
wherein 6,579 physicians from northern Portugal were gathered to participate in 2008.
After conducting randomization, Herdeiro et al. (2012) put 1,034 physicians in a group
conducting telephone-interview interventions, and 438 in a group under the category of
workshop intervention. The remaining physicians were categorized as the control group
(Herdeiro et al., 2012).
At the workshop, a real clinical case was demonstrated and the physicians were
asked to report on it by completing the necessary forms (Herdeiro et al., 2012). In the
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over-the-phone intervention, the physicians answered questions pertaining to whether
they had ever suspected ADRs and whether they suffered any challenges when it came to
reporting these (Herdeiro et al., 2012). They were also asked whether they could recall
the methods for reporting ADRs and whether they found it important that they, as
physicians, had a hand in the reporting process, faced difficulties in reporting, propose
different method of reporting, or value reporting adverse events (Herdeiro et al., 2012).
Statistical analyses of data from all groups revealed that the workshop
intervention had the ability to increase spontaneous ADR reporting rates by an average of
400% up to 20 months after intervention (Herdeiro et al., 2012). On the other hand,
telephone interventions were not found as efficient or effective. They led to no significant
increase in spontaneous ADR reporting in comparison to the control group (Herdeiro et
al., 2012). Still, for the first four months, telephone interventions did increase
spontaneous reporting (Herdeiro et al., 2012). Based on the study of Herdeiro et al.
(2012), it could be concluded that interventions in general could improve spontaneous
ADR reporting. However, workshops were better at increasing both the quantity and
relevance of spontaneous ADR reporting for a longer time.
Lorimer, Cox, and Langford (2012) analyzed the influence of ADRs on patients
and their views on reporting. The researchers interviewed the patients who experienced
an ADR and were admitted in an inner city hospital. The researchers found that most of
the patients were afraid of being admitted to the hospital. More than anyone, they
expected the healthcare professional to prescribe the medication that would not cause
harm and to be the expert medication treatment (Lorimer et al., 2012). The patients rarely
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read the patient information leaflet. As such, when an adverse reaction occurred after
taking a medication, few of them associated the adverse effects with the medication.
Some of them, however, received false reassurance that the drugs were not behind the
adverse event or the illness. These factors led to additional barriers to accurate reporting
of adverse reactions. A majority of the patients believed that adverse drug reporting
should not be their responsibility (Lorimer et al., 2012).
From the 1970’s to the 1980’s, intensive monitoring had emerged as another
descriptive method of identifying ADRs in New Zealand and the UK, which was called
Prescription Event Monitoring. Under this method, prescription data was utilized to
determine who the users of a specific drug were. The prescriber was questioned on any
incidences of adverse event that took place when the drug had been in use. The data
gathered from the prescriber were considered as new signals (van Grootheest &
Richesson, 2012). The benefits of intensive monitoring were many. First, the findings of
this method were not affected by the kind of selection and exclusion criteria the same
very clinical trials were. Moreover, because identification of ADRs was done through
monitoring, this could result into the identification of signals for events that were not
initially perceived as ADRs of the drug being monitored. In addition, this method could
lead to the estimation of how frequent the ADRs of a certain drug took place, thereby
made it possible to quantify the risks of ADRs (van Grootheest & Richesson, 2012).
When a new drug was approved, its safety could only be ascertained through the
responses of the several thousand people who took it during clinical trials. However, once
it entered the market, the real safety testing got under way. Within a year or two of
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introduction, the number of people who were exposed to the medication and its effects
might rise significantly into millions, especially if the drug manufacturer practices
rigorous and aggressive marketing and advertising through television, print and more
others (Okie, 2005). If the drug had dangerous and yet unusual side effect, for instance,
liver failure that was only suffered by one in 1000 patients, that effect would normally be
acknowledged and determined only after the medication had already been taken by
millions of users. In addition, if the drug increases the occurrence of a common
condition, for instance, myocardial infarction, this risk could only be recognized after a
million of people had used the drug as well (Okie, 2005). Almost 50% of the drugs that
were introduced to the market had serious adverse effects that were only recognized once
they were already approved (Okie, 2005). What was worse that most Americans were
usually the test population. Because of the quicker review of product applications
conducted by the FDA, at least 60% of new drugs were always approved first in the
United States, unlike decades ago, when drugs were often approved in other countries
(Okie, 2005).
This shift led to a parallel increase in the attention given by experts, lawmakers,
consumer advocates and federal officials to drug safety. They call for better ways of
monitoring the effects and safety of already approved drugs (Okie, 2005). The fact that
more Americans were taking prescription drugs served to make the calls more urgent. In
2004, pharmacists had filled 3.1 billion prescriptions, around 60% of which were more
than 10 years earlier. Reports to the FDA of drug-related adverse reactions had also
heightened correspondingly and now total of 375,000 annually, more than double the
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number a decade ago (Okie, 2005). These figures were alarming considering the agency's
current surveillance system was passive, depending on the diligence of drug companies
only, as well as the reports of healthcare providers and consumers (Okie, 2005).
According to policy experts, a new system should be in place to obtain
observational data on significant numbers of people who were vulnerable to medications
being introduced to the market (Okie, 2005). The information might be collected from
databases as they were increasingly accessible through many managed-care networks and
other providers shifted to the use of electronic medical records (Okie, 2005). According
to Kuehn (2012), IOM called for the FDA to be more aggressive and proactive in
responding to the safety concerns that emerged after a drug had been introduced to the
market.
Based on the study of Dart (2009), the main purpose of post-marketing
surveillance was for the FDA to provide accurate information on the risks associated with
a drug. Drugs that affect the central nervous system comprised a group of products that
should be surveyed because they were usually used inappropriately either by misusing
them, abusing them or diverting them (Dart, 2009). Examples of these medications were
opioid analgesics, stimulants, sedative-hypnotics, muscle relaxants, anticonvulsants and
more other drugs (Dart, 2009). The adverse events associated with these drugs were
complex to monitor because the perpetrator was usually determined to hide the misuse,
abuse and diversion of the drug (Dart, 2009). As such, an effective post-marketing
surveillance system for prescription drug would be one that provides specific information
that was accurate, accessible and geographically specific. The FDA had put forward a
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memo stating that all products containing high level of opioid drugs should be subjected
to aggressive surveillance and risk management (Dart, 2009).
Criticisms of Pharmacovigilance Systems
Throughout the years, the FDA as well as the whole system of post-marketing
surveillance received heavy criticisms (Furberg, Levin, Gross, Shapiro, & Strom, 2006;
Lenzer, 2004; Mitka, 2006; Ray & Stein, 2006; Strom, 2006). Critics heavily denounced
FDA for being limited and ineffective because it only used restricted number of data
sources such as clinical trials and spontaneous reports to determine the safety of the
drugs. Moreover, the FDA was criticized as not having legitimate control for carrying out
and completing post-marketing safety studies (van Grootheest & Richesson, 2012, p.
371). According to Furberg et al. (2006), the FDA needed serious changes because the
initial preapproval studies were designed in a way that prevented serious adverse events
from detection. Moreover, massive underreporting of adverse events to the FDA postmarketing surveillance system made FDA assessments of risks inaccurate. The FDA was
unable to go after the sponsors and manufacturers who did not fulfill or ignore their postmarketing safety study obligations. Lastly, the FDA was perceived as becoming more
closely linked to the regulated pharmaceutical industry and weak when it came to their
oversight abilities.
Moreover, most post-marketing study commitments that had been planned were
never carried out. From 1970 to 1984, around 38% of post-marketing safety studies were
not completed (van Grootheest & Richesson, 2012). However, even though this was the
case, the FDA did not have the authority to take direct legal action against these
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companies who did not follow through with their commitments (van Grootheest &
Richesson, 2012). The FDA was said to have become too close to the industry it was
supposed to be regulating. The critics claimed that regulatory duties of the institution
should be separated from its post-marketing surveillance activities (van Grootheest &
Richesson, 2012). The FDA reacted to this criticism by asking the IOM to evaluate the
US drug safety system. As such, in September of 2006, the IOM produced a report that
claimed the FDA should monitor the safety of a drug during its whole life cycle or should
follow the life cycle approach. By following this approach, the FDA should determine
safety signals, design studies that would confirm these signals, assess both the benefits
and risks of drugs, and utilize risk-benefit assessments to integrate study results and
disclose the main findings to patients and physicians (Psaty & Burke, 2006)
FDA’s Adverse Event Reporting System
According to Hoffman, Overstreet and Doraiswamy (2013), more than 770,000
injuries or deaths annually could be attributed to adverse events linked to drugs already
approved by the FDA. It had been estimated that around 28% of these adverse events
could have been prevented if there was an effective computerized monitoring system in
place. The FDA currently had a database of these drug-related adverse events, which was
the FAERS as well as an adverse event database for medical devices, was called
Manufacturer and User Facility Device Experience (MAUDE).
The FAERS was a database that consisted of information on the reports received
by FDA containing information of adverse events and medication errors. The database
was designed to supplement the body's post-marketing safety surveillance of drugs and
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biological products. The FAERS abided with the international safety reporting guidance
provided by the International Conference on Harmonization (Sakaeda, Tamon,
Kadoyama, & Okudo, 2013).
This system acted as the post-market monitoring system for the FDA, which used
historical data or information to supervise new adverse events and medication errors from
drug and therapeutic biologic products (FDA, 2012d). This was designed to control the
medical treatment and drug related issues that might lead to hazardous effects to the
patients and consumer. The idea of recording and creating a computerized information
database started due to the number of adverse events in the United States that was
claimed to be 1 million every year, of which 44,000 to 98,000 was claimed had ended as
fatalities (Leape, 2002).
At present, FAERS was considered the largest database of spontaneously reported
adverse events and medication errors worldwide (Moore, Cohen & Furberg, 2007). At
present, this database already contained 4 million reports of these adverse events. The
FDA distributed the data under this system to the public and the public access enabled the
researchers or experts to conduct pharmacoepidemiological or pharmacovigilance studies
(Sakaeda et al., 2013).
The FAERS database had been utilized for analyzing the safety profiles of many
different drugs. In addition, the highly suspicious drugs linked to serious adverse events
were found by using the FAERS database, examples of which were the torsades de
pointes (Poluzzi, Raschi, Motola, Moretti, & De Ponti, 2010). “Torsade de pointes is a
form of polymorphic ventricular tachycardia occurring in a setting of prolonged QT
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interval on surface electrocardiogram” (Gowda, et al., 2004, p.1). Through a larger
number of reliable reports, the FAERS database, as well as other databases for reporting
could lead to optimized pharmacotherapy (Sakaeda et al., 2013).
The FAERS had its advantages and limitations. The system did not necessarily
have known disadvantages yet, but rather limitation in terms of the design. Despite the
benefits of the system, it had its limitations, similar to other systems. The main limitation
of the current FAERS was that the reports submitted to the FDA and integrated into the
system lacked the comprehensive details of the consumers who experienced the adverse
events or medication errors due to underreporting, differential reporting as well as uneven
quality (Berlin, Glasser, & Ellenberg, 2008; Hochberg, Pearson, O’Hara, & Reisinger,
2009).
In general, adverse events were still underreported even with the emergence of
spontaneous reporting systems (Figueiras, Herdeiro, Polonia, & Gestal-Otero, 2006;
Hazell & Shakir, 2006; Lopez-Gonzales, Herdeiro, & Figueiras, 2009). While the rate of
reporting might depend on the specific adverse event, the average rate of reporting was
just 6% based on 37 studies (Hazell & Shakir, 2006). Various factors could explain why
many adverse events were still not being reported, but the most critical one concerns the
knowledge and attitude of health professionals (Lopez-Gonzales et al., 2009). Moreover,
an educational intervention had shown to be the key to improve the rate of reporting
(Figueiras et al., 2006). Through a patient-targeted survey, it was determined that 87% of
patients relied on their physicians to establish if there was a possible connection between
the adverse event and the use of statins; however, it was found that physicians had the
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higher tendency to say no to the possibility rather than affirm the link (Golomb &
McGraw, 2007). In addition, increased publicity and patient education for the FAERS
were also important to encourage patient reporting (Du, Goldsmith, Aikin, Encinosa &
Nardinelli, 2012). Currently, while the report rate had improved with the implementation
of the FAERS (Rodriguez, Staffa & Graham, 2011), it was still not ideal to use the
FAERS database in estimating incidence report rates because of the lack of a
denominator, which signified the population size to determine utilization together with
the number of times it occurred.
According to the FDA (2012a), adverse events and medication errors that had
been made by healthcare professionals or experienced by consumers were not strictly
mandated to be reported, reporting was voluntary in the United States. The adverse event
and medication error reports were sent to the FDA by the consumers or end-users (for
example, physicians, pharmacists, nurses, and other healthcare professionals) (FDA,
2012a). More so, these said individuals who had first or second-hand experience of the
adverse events or medication errors might directly contact the products’ manufacturers to
report the problem. The FDA expected to receive the complaint report from the
manufacturer filed by the consumers or healthcare professionals, as this process was to be
done as it was stipulated in the regulations. All reports were then integrated in the
FAERS, after which it was directly sent to the FDA or reported to the manufacturers
(FDA, 2012a).
According to Hoffman et al. (2013), FAERS had the ability to acquire 700,000
reported adverse events annually across different therapeutic categories, making it a
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powerful database. The database was widely used by many regulatory agencies and the
pharmaceutical industry to look for data regarding drug safety. However, Hoffman et al.
(2013) raised the problems with FAERS, such as the issue of complexity and costliness
of proprietary data mining and signaling tools utilized by the regulatory agencies and
major pharmaceutical companies. In addition, only those familiar with relational
databases could obtain publicly available FAERS information, which limits the use of
this database. This was why; the FAERS database was still currently mostly inaccessible
to majority of physicians, pharmacists and consumers.
In addition, FAERS also suffered from limitations such as duplicate reporting,
masking, amplifications, and insufficient information (Hoffman et al., 2013). The data on
the FAERS might not be reliable because physicians might disproportionately report
effects linked to newer drugs, even though other influence of other prescribed drugs and
other factors might be the real cause of the adverse events. Data might also be
questionable because physicians might have been influenced by publicity and marketing
conditions. The lack of true incidence rates as well as accurate usage data could make the
data in the FAERS unreliable (Hoffman et al., 2013).
Sentinel Initiative
To develop and implement the Sentinel System, the FDA performed pilot
programs to aid in the forming of scientific methodologies, identifying data infrastructure
needs, and enlightening the agency on how to establish strong data governance to form an
accurate governance structure to ensure data privacy and security (Robb et al., 2012).
During these earlier periods of development and implementation, the FDA discovered
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that a distributed data system model involving voluntary participants was the key
approach that could be used for coming up with an active safety surveillance system.
Through this surveillance model, the FDA could make sure that data would stay in its
local environment, unlike to a centralized approach, which would entail the consolidation
of all data into one physical location (Robb et al., 2012).
The Mini-Sentinel pilot project was comprised of 20 organizations, led by the
Harvard Pilgrim Health Care Institute (HPHCI) (Robb et al., 2012). The Mini-Sentinel
program was a pilot under the FDA Sentinel initiative, as an effort to implement a
national system that would assess the safety of medical products. The Mini-Sentinel was
focused on signal refinement, or the improvement in the process of the assessing the
magnitude of suspected links between specific medical products and specific adverse
health outcomes (Robb et al., 2012). The FDA selected the particular product-outcome
pairs, as it was the body most knowledgeable of the product. Under this program, the
FDA differentiates between signal generation, signal refinement as well as signal
evaluation (Robb et al., 2012). Signal generation involved the carrying out of statistical
methods to discover possible safety signals among the pairs of non-pre-specified medical
products and specific adverse outcomes. On the other hand, the process of signal
refinement involved the identification of possible safety signal to establish more clearly
whether evidence existed to provide a basis for the particular product-outcome pairs.
Lastly, signal evaluation involved the attempts to assess the causal links between specific
medical products and adverse outcomes by conducing epidemiological analysis (Robb et
al., 2012). The Mini-Sentinel did not engage in data mining or other signal generation
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operations as part of its standard practice. However, these activities were still included in
the Mini-Sentinel Post-Licensure Rapid Immunization Safety Monitoring or PRISM
program that was already exploring this capability in federal vaccine monitoring
activities (Nguyen, Ball, Midthun & Lieu, 2012). The ongoing Mini-Sentinel hoped to be
able to do the whole spectrum of surveillance activities, or in other words, it was able to
carry out signal generation, to signal refinement and then to signal evaluation activities.
The collaborators behind the pilot project had worked since 2011 to assess some
of the important issues for forming active medical product surveillance system in the
United States (Robb et al., 2012). This included the best statistical and epidemiological
approaches to use and what data and infrastructure were necessary for accurate
surveillance investigations. The collaborators also assessed what kind of governance
structure would have to be in place to support the initiative. Mini-Sentinel had been
successful in serving as a general-purpose vaccine safety monitoring system (Robb et al.,
2012).
Platt et al. (2012) assessed the Mini-Sentinel program, which designed different
methods, tools, resources, policies, and procedures that could be used for the collection,
analysis, and surveillance of electronic healthcare data. The data collected encompassed
drugs, biologics, as well as medical tools (Platt et al., 2012).
Within two years of its existence, the Mini-Sentinel program had 31 academic and
private organizations associated with it (Platt et al., 2012). Platt et al. (2012) found that
the Mini-Sentinel program employed various activities such as the robust surveillance of
a wide range of drugs and vaccines, as well as the improving of the common data model
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to secure additional types of data. The data were sourced from different electronic health
records and registries. The Mini-Sentinel program also had the ability to form or design
new methodological capabilities and provided an approach to identifying and verifying
additional and relevant health outcomes (Platt et al., 2012).
According to Forrow et al. (2012), the Mini-Sentinel Program was remarkable
because it had its own organizational structure as well as principles that regulated its
operations. These policies and structures allowed it to influence the structure and purpose
of the Sentinel System (Forrow et al., 2012). The Mini-Sentinel program was also
committed to the goal of the Sentinel Initiative, which was to ensure drug safety by
regulating the ADRs of drugs already marketed to the public (Forrow et al., 2012). The
program abided by the principles and regulations that uphold fair information practices
(Forrow et al., 2012). As such, the privacy of individuals and the confidentiality of
healthcare data were observed. Still, the success of this initiative still remained largely
upon the users’ satisfaction (Forrow et al., 2012).
Effects of Pharmacovigilance
According to Behrman et al. (2011), the FDA Sentinel Initiative served as an
additional tool for the FDA to evaluate the safety of medical products, and more
importantly, acted as a national resource for the FDA to take advantage of investigating
medical product performance. Moreover, the Sentinel Initiative became an early working
model for secondary uses of data, and a national resource of a learning healthcare system.
Robb et al. (2012) explained that the FDA Sentinel Initiative was borne from responses to
the congressional mandate in Section 905 of the FDA Amendments Act of 2007. This
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initiative was intended to provide advantage to existing healthcare information to allow
the FDA to perform active post-market safety surveillance in support of the current
surveillance systems it had (Robb et al., 2012).
According to Robb et al. (2012), the idea of secondary use, or utilizing data
collected for other intentions, such as electronic health record data initially recorded for
patient care or insurance claims data utilized for reimbursement was not a new one.
Nonetheless, due to the expansion of the availability of these types of data, based on the
passing of the US Health Information Technology for Economic and Clinical Health
(HITECH) Act, more attention had been given to the leveraging of these data for
purposes they were not intended for, such as updating the public on specific health issues.
One of these issues was the safety surveillance of medical products (Robb et al., 2012).
The FDA, through the use of various administrative and claims databases, as well as
electronic health record systems and registries, would now have the ability to scrutinize
regulated medical products nearly as fast as real time and to better comprehend product
safety (Robb et al., 2012).
According to Robb et al. (2012), the system being designed and developed under
the auspices of the Sentinel Initiative would be able to aid the FDA in discovering and
analyzing post-market safety signals through signal generation, signal refinement, and
signal evaluation, which referred to the concern over an excess of irregular and negative
events when compared to what was traditionally associated with a product's use. Signal
refinement specifically allowed the FDA to assess a drug at various times during its life
cycle (Robb et al., 2012). Should a drug be assessed to lead to adverse outcomes, the
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FDA might conduct additional assessments to validate the signals it received. The
validation process was performed to ensure that the adverse outcome from the drug was
not spurious (Robb et al., 2012). Overall, the Sentinel Initiative was helpful to the FDA
when making regulatory decisions.
Summary
The current FDA consumer safety surveillance system used the FAERS, which
had limitations, including not allowing real time data collection. In response to these
limitations, the FDA launched the Sentinel Initiative in 2008 (Platt et al., 2012). This
study provided a comparative case study between the two systems, investigating the
influence of the Sentinel Initiative on users of FAERS.
The review of literature outlined the existing knowledge pertinent to this study. It
illuminated the need for ADR reporting systems and their benefits. It also specifically
covered the Sentinel Initiative and the Mini-Sentinel Program, which were the programs
of interest for the proposed study.
The next section covered the methodology used in carrying out the proposed
study, which was approved by Walden IRB committee. The study implemented a
comparative case study design, which was qualitative in nature. Survey questionnaires
used to determine the perceptions of the participants regarding the costs and benefits of
the Sentinel Initiative compared with the current FAERS surveillance methodology. The
data analysis technique that used was content analysis, which involved the development
of thematic categories and themes from qualitative data.
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Chapter 3: Research Methodology
The purpose of the comparative case study of the current FAERS surveillance
system and the new FDA Sentinel Initiative was to determine the potential impact and
benefits of the Sentinel Initiative in terms of consumer safety. Currently, the reporting
system used by the FAERS was voluntary and quarterly, and data was entered from the
point of care (Powers & Cook, 2012). Instead of depending on point-of-care data
collection, the Sentinel Initiative had access to multiple existing data systems such as
electronic health record systems and medical claims databases in real time (Platt et al.,
2009).
This was a qualitative study was focused on the perceptions of individuals who
had worked closely with the FAERS program and were familiar with the Sentinel
Initiative. As such, no quantification of data waswas carried out to compare information
on the two programs. Instead, the responses of participants regarding their perceptions
was used to illustrate differences between the two programs. In this study, the two cases
referred to the perceptions of the FAERS and perceptions of the Sentinel Initiative. This
chapter presents details of the design, sampling and sampling methodology, data
collection methodology, and data analysis.
Research Design and Rationale
In general, qualitative studies were different from quantitative studies in the sense
that qualitative studies permit the study of a particular phenomenon in depth within the
participants’ natural settings (Denzin & Lincoln, 2005). Qualitative research is
advantageous due to the richness of data gathered especially when data gathering was
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performed through interviews, which allowed interviewees to expound on their answers
without being limited by the predetermined choices for answers or the need to write down
answers to questions (Moriarty et al., 2011). Qualitative designs were beneficial when
existing research in an area was limited. Moreover, given the limitations of time,
qualitative data was considered appropriate for this study.
Case studies were qualitative methods that allowed for in-depth and multifaceted
explorations to generate rich knowledge about a given subject (Crowe et al., 2011).
According to Zainal (2007), case study enabled the researcher to explore and understand
complicated issues. Case study research could be considered a robust approach for
understanding issues holistically and deeply (Zainal, 2007). Researchers who used a case
study method could closely analyze the data gathered within a specific context (Zainal,
2007). The method was also appropriate for studies with a small geographical area or a
very limited number of participants. It was also the best method for investigating real-life
issues because it allowed for a detailed contextual analysis of a small number of events as
well as conditions and their relationships to each other (Zainal, 2007).
According to Zainal (2007), case studies had various advantages. Case study
research allowed for examination of data within the situation in which the activity
happened. Moreover, the case study method allowed the researcher to explore or
characterize the data within real-life contexts as well as explained the complexities
associated with the real-life issues that survey research or experimental methods could
not capture (Zainal, 2007). When multiple cases were examined and compared, then it
was called a comparative case study (Abadie, Diamond, & Hainmueller, 2010). In this
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study, the first case was the perceptions of the old system and the second case was the
perceptions of the new system.
Methodology
Population
The target population included safety professionals from drug companies who had
self-reported knowledge or expertise in assessing consumer impact. The participants were
selected from various departments within pharmaceutical companies and across
geographical locations. The participants were subject matter experts in the field of
pharmacovigilance.
Sample and Sampling Procedures
Samplingincluded participants at different levels from different therapeutic
departments such as pain and inflammation, cardiovascular, and psychiatric and mental
health. The geographical locations included selected pharmaceutical companies in the
United States. The participants were(a) had worked closely with the current FAERS
surveillance system and were familiar with the FDA’s Sentinel Initiative and (b)were
from prominent pharmaceutical companies involved in the programs of focus in this
study. Criteria confirmation waswas performed by asking participants questions that
conformed to the criteria for inclusion during the time the interview was to be scheduled.
Mason (2010) stated that the required sample size for qualitative studies could be
determined based on the point of data saturation. Saturation indicated that the data
gathered had reached consensus, and using more resources by recruiting more
participants would result in marginal increases in new data (Mason 2010). Yin (2003)
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posited that qualitative case studies usually had small sample sizes as opposed to
quantitative methodology, which normally relied on larger sample sizes. Polkinghorne
(2005) stated that qualitative data were collected in the form of written or
verbal language, and the sample size was not the primary focus. In addition,
Patton (2005) stated that there were no specific standards for sample size in qualitative
studies, and that, “sample size depends on what you want to know, the purpose of the
inquiry, what’s at stake, what will be useful, what will have credibility, and what can be
done with available time and resources” (p. 244). However, a sample size of 10-20
participants was usually considered sufficient to achieve data saturation because a review
had shown that the small sample size could facilitate gathering enough detailed accounts
of personal experiences to arrive at a consensus among answers (Mason, 2010). Hence,
20 participants who had worked closely with the FAERS program and were familiar with
the Sentinel Initiative were recruited for this study.
For sampling methodology, purposive sampling was used with the snowball
technique for more efficient recruitment of participants. According to Latham (2007),
purposive sampling referred to choosing a sample based on the researcher’s knowledge of
the population and its elements and matching these elements to the nature of the research
aims. As such, the population was not randomly selected. Instead, they were chosen
because they could answer the questions regarding a specific matter or product. This
method was best for research studies that included subjects who are part of a larger
population that were easily identified but enumerating them all was impossible (Latham,
2007). In addition to purposive sampling, snowball sampling was another sampling
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technique used. Snowball sampling took advantage of social ties and network referrals of
potential participants who possessed the characteristics for inclusion in the study
(Latham, 2007). According to Latham (2007), this would include the researcher
depending on previously identified subjects to identify others who had similar
characteristics. To recruit samples using purposeful sampling with snowball sampling,
the participants were sought within pharmaceutical companies in the United States who
were selected because of their involvement with the FAERS program. Participants were
only those who met the inclusion criteria of having worked with the FAERS and were
familiar with the new Sentinel Initiative. The nature of the study was discussed with the
participants. The contacted participants referred the study to other individuals who fit the
inclusion criteria. The prospective participants were contacted through formal invitation
letters.
An informed consent form (Appendix B) was attached with the formal invitation
letter (Appendix A) sent to potential participants. The informed consent form included a
brief description of the study, the purpose, and the role of the participants. Participants
were also informed that their interviews would be recorded. Once the potential
participants agreed, they signed the informed consent to signify their acceptance of
involvement in the study. After signing the informed consent, the participants brought the
forms to the interview; unsigned forms were also available during the interview for
participants who had forgotten to bring their signed forms. The participants were
contacted via telephone or email to arrange a convenient date and time for the telephone
interview. Telephone interview was more convenient because of geographical distance
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and reduced the travel burden for the participants. Specifically, each participants’ was
asked for his or her consent prior to the beginning of the telephone interview. The
telephone interview lasted approximately 45 minutes. Participants who preferred the
telephone interview faxed or emailed the copies of their informed consent with their
signatures.
Data Collection
Data collection was facilitated with the use of semi-structured interviews. Prior to
the interview, the participants were reminded of the content of the informed consent.
They were also reminded that participation was voluntary, that their identity would be
kept confidential, that the interview would be recorded, and that all files and notes would
be kept secured inside a locked cabinet in a private office and would be destroyed after 5
years from the completion of the study.
To facilitate the semi-structured interviews, an interview guide was used that
contained questions that were focused on gathering answers that were in line with the
purpose of the study. To make sure that the participants could easily and accurately
understand the questions in the interview guide (Appendix C), a pilot study was
conducted for comprehensibility. In the pilot study, five participants were recruited with
the same qualifications to participate in the interview (from the pharmaceutical
companies selected for this study). These pilot study participants interpreted each
question and discussed their feedback during a one-on-one session after the completion of
the interview. Notes were taken of the feedback and no change in the interview guide was
required after the pilot study was completed. At the end of the interview, the participants
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were thanked. The participants were given an opportunity to ask questions and request
clarifications, which were addressed.
Though the interviews were expected to last 45 minutes, there was no time limit
as each interview was dependent upon the flow of the conversation between me and the
respondent. The entire data collection process, which included the recruitment process,
pilot study, and completion of the 20 interviews, lasted twelve weeks during Fall 2015.
Data Analysis Plan
To analyze the transcribed data, thematic content analysis was used. Content
analysis led to the identification of important themes. Content analysis was “a research
method for the subjective interpretation of the content of text data through the systematic
classification process of coding and identifying themes or patterns” (Hsieh & Shannon,
2005, p. 1278). The thematic pieces were weaved together to form an integrated picture
that was aligned with the research questions, which were as follows:
Research Question 1: What are the prospective benefits of the FDA’s Sentinel
Initiative as compared with the FAERS surveillance methodology?
Research Question 2: What are the challenges and negative impacts of the FDA’s
Sentinel Initiative as compared with the FAERS surveillance methodology?
Research Question 3: What are the lessons learned that can enhance the scope of
the Sentinel Initiative?
According to Polit and Beck (2004), the researcher began the analysis of data by
looking for themes, which involved looking for commonalities, natural variations, and
patterns across the responses of the participants. To uncover themes for this study, the six
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steps of Braun & Clarkes’ (2006) thematic analysis were used as a guide, which consisted
of the following:
1. Familiarization with the data: This involved transcribing, reading, and rereading the audio-recorded interview data, and taking note of initial ideas.
Final raw data was the transcripts for each of the interview sessions.
2. Codes generation: Code of interesting features of the data were developed in a
systematic fashion as applied to the entire data set. The entire data set was
coded based on the coding scheme developed.
3. Searching for themes: the codes were collated into potential themes by
gathering all data relevant to each potential theme.
4. Theme review: The themes were checked in relation to the coded extracts and
the entire data set. Through this step, a thematic map of the analysis was
generated.
5. Theme definition: Themes represented the most cited codes within a category.
Codes, categories, and themes were analyzed. These were defined accordingly
based on the codes they contained. Codes represented the smallest unit of idea
or information relevant to the study. Categories were composed of interrelated
codes that pertained to a larger but similar idea.
6. Report generation: The final report of the data analysis was developed and
selected vivid and compelling examples to further explain the findings. For
each category, tables contained the codes that emerged from that category.
Themes represented the recurrent ideas that emerged from the data.
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All of the responses were read and analyzed; then extracted the significant
statements that pertained directly to the issue. Following this, meanings for significant
statements were formulated and categorized these into clusters, which were considered to
be the themes. Following these steps, the findings were integrated into an exhaustive
description. Then a comprehensive description of the phenomenon under study was
formed.
Validity
The participants were recruited for the study. The semi-structured interviews with
the 20 participants were conducted. It was ensured that the sessions were productive in
eliciting useful information from the participants by following the proper techniques for
one-on-one interviews. The interview guide was followed to ensure validity and
reliability. It was ensured the study was not impacted by any bias to ensure that data was
accurate and objective. To minimize bias, the study’s credibility, dependability, and
transferability was upheld. Below were the ways to ensure these respectively.
Credibility and Dependability
To ensure credibility, member checking were performed through verification of
accuracy of conclusions with participants (Thomas & Magilvy, 2011). The researcher
was as transparent as possible with the participants, by sharing the interpretations and
conclusions with them. Member checking was performed to double check if the
information transcribed and written corresponds to what the participants said (Thomas &
Magilvy, 2011). Member checking was done by asking participants to review the
transcript and solicit feedback regarding the transcript accuracy. To ensure dependability,
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the researcher audiotaped interviews, with the consent of the participants, and later on,
the researcher transcribed the interviews verbatim. An audit trail had been kept and used
by the researcher where observations were recorded and made available for peer
reviewers (Thomas & Magilvy, 2011). Pseudonyms, known to the researcher alone, were
used to replace all these identifying information and transcript of a participant. For report
generation, aggregate data was used; for instances that required the researcher to single
out a particular data point, pseudonyms was used instead.
Transferability
Thomas and Magilvy (2011) claimed the association between transferability and
external validity. Transferability involved the study’s ability to transfer findings to
another population different from the one used by the researcher of the original study
(Thomas & Magilvy, 2011). All the data collected, audiotapes, and journal notes, and
transcriptions were kept in their original form. This was done to allow easier access
should there be a need to recreate the study in a different setting. The data did not contain
any names. Pseudonyms, known to the researcher alone, were used to replace all these
identifying information to ensure the confidentiality of the participants.
Ethical Procedures
Researchers needed to ensure that they recognized and protected the rights and
general well-being of their participants (Resnik, 2010). Ethical lapses in research could
harm human and animal subjects, students, and ultimately, the public (Resnik, 2010).
Before participants actually took part in the study, they were asked to sign an informed
consent containing the details of the study and the information they needed to know as
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they partake in the study. The ethical issues covered by the informed consent were
confidentiality and voluntary nature of participation. Upon agreeing, the participant was
to sign the consent form as proof that they agreed to participate in the study.
Confidentiality was an important issue that must be addressed in using human
participants in a research. To do this, any information was deleted that might identify the
respondents in any way. Pseudonyms, known to the researcher alone, were used to
replace all these identifying information. For report generation, aggregate data was used;
for instances that required to single out a particular data point, pseudonyms was used
instead. The participants were also informed that the interview would be recorded. After
transcribing, each respondent could review the transcripts of their interviews for mistakes
and make requests for removal of any undesirable word or phrase. This process was
called member checking. According to Harper and Cole (2012), member checks were
important to make sure that an authentic representation was made of what was expressed
during the interview sessions.
Being a participant in the study was voluntary; and hence, they would or would
not agree to sign the consent form. Voluntary participation also implied that there was no
reward or consequence for being a participant of the study. Even if they had already
consented to participate, participants still had the option of termination their participation
of the study, without having any consequence on their part. They also had an option to
choose not to answer any particular question, which they felt uncomfortable answering.
All files containing data related to the study, including all physical and electronic
files like audio recording, interview transcripts, printed documents, and other notes, were
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kept inside a locked cabinet located at a private office where I had access to these files.
These files would be kept for five years after the entire study had been finished and
completion of this dissertation. After five years, they would be destroyed through
shredding or burning.
Summary
The purpose of this comparative case study of the current FAERS surveillance
system and the new FDA's Sentinel Initiative was to determine the impacts and benefits
of the Sentinel Initiative in terms of consumer safety. Currently, the reporting system
utilized by the FAERS was voluntary and quarterly (Powers & Cook, 2012). Instead of
depending on point of care data collection, the Sentinel Initiative would access multiple
existing data systems such as electronic health record systems and medical claims
databases (Platt , Wilson, Chan, Benner, Marchibroda, & McClellan, 2009).
This was a qualitative study focusing on the perceptions of individuals who
worked closely with the FAERS program and were faimiliar with the new Sentinel
Initiative. As such, no quantification of data was carried out to compare information on
the two programs. Instead, the responses of participants regarding their perceptions were
illustrated any differences between the two programs. This chapter showed that the
research questions are in line with the purpose of the study, a comparative case study
approach was chosen for this study. Semi-structured interviews were used to gather data
for the study from 20 participants who worked with the FAERS program and familiar
with the Sentinel Initiative. Participants were recruited using purposive sampling and
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snowball sampling. To analyze data, content analysis was used. The next chapter will
discuss the details of the data gathered for the study.
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Chapter 4: Results
The purpose of this comparative case study of the current FAERS surveillance
system and the new FDA’s Sentinel Initiative was to determine the potential impact and
benefits of the Sentinel Initiative in terms of consumer safety. Currently, the reporting
system utilized by the FAERS is voluntary and quarterly, and data was entered from the
point of care (Powers & Cook, 2012). Instead of depending on point-of-care data
collection, the Sentinel Initiative had access to multiple existing data systems such as
electronic health record systems and medical claims databases in real time (Platt et al.,
2009). There were differences between the FAERS and the Sentinel Initiative that were
identifiable by the pharmacovigilance experts.
The following were the research questions of this study:
RQ1. What are the prospective benefits of the FDA’s Sentinel Initiative as
compared with the FAERS surveillance methodology?
RQ2. What are the challenges and negative impacts of the FDA’s Sentinel
Initiative as compared with the FAERS surveillance methodology?
RQ3. What are the lessons learned that can enhance the scope of the Sentinel
Initiative?
FAERS was known to be a useful tool for the FDA to ensure compliance with
reporting regulations and responding to outside requests for information. The reports in
FAERS were evaluated by the FDA and clinical reviewers in the Center for Drug
Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research
(CBER). The main goal of the FAERS surveillance system was to ensure the protection
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and safety of the consuming public (FDA, 2016). The Sentinel System enabled FDA to
actively query diverse automated health care data holders - like electronic health record
systems, administrative and insurance claims databases, and registries - to evaluate
possible medical product safety issues quickly and securely. The FDA Adverse Event
Reporting System (FAERS) was a database that recorded the relevant information on
adverse events of drugs or medication errors that were submitted to FDA (FDA, 2016).
The database of the FDA was designed to support the FDA’s program for the
safety surveillance of pharmaceutical medications for drug and therapeutic biologic
products. FAERS captured data by either consumer reporting directly to drug
manufacturers or by calling the FDA directly and which is why there was a limited set of
information going to system. On the other hand, the FDA’s Sentinel Initiative was a
national electronic system that would allow the FDA to track the safety of medications,
medical devices, and drugs upon reaching the market. The FDA was able to query
consumers and examine the health record systems to ensure that drugs were safe for
human consumption (FDA, 2016). The Sentinel System allowed the FDA to monitor the
safety of drugs and medical products including devices with the assistance of many
collaborating institutions throughout the United States. Data partners in this initiative
included medical centers, health maintenance organizations (HMOs), and health care
systems like hospitals (FDA, 2016).
Pilot Study
To facilitate the semi-structured interviews, an interview guide was used that
contained questions focused on gathering answers that were in line with the purpose of
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the study. To make sure that the participants could easily and accurately understood the
questions in the interview guide; a pilot study was conducted for comprehensibility. Five
participants were recruited with the same qualifications to participate in the interview
(from the pharmaceutical companies selected for this study). These pilot study
participants interpreted each question and discussed their feedback during a one-on-one
session after the completion of the interview. At the end of the interview, the participants
were thanked.
Five participants were recruited for the pilot study. The participants worked in
pharmaceutical companies and had experience in the pharmacovigilance department. The
participants were interviewed separately and their feedback was sought about the content
of interview questions. No change in interview guide was required. Data collection was
continued with other participants.
Setting
The participants included safety professionals from drug companies who had selfreported knowledge or expertise in assessing consumer impact. The participants were
selected from various departments within pharmaceutical companies and across
geographic locations. The participants were subject matter experts in the field of
pharmacovigilance. The setting of the study emphasized the importance of reporting the
adverse impacts of medication and drugs.
Summary of Demographic Information
The study included 20 interviewees who had different numbers of years of
experience in the field of pharmacovigilance. All participants had worked in major
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pharmaceutical companies and had previous experience in pharmacovigilance
departments or were working in the departments at the time of the study. The participants
were taken from different levels in their respective pharmaceutical companies, including
junior level and senior levels positions. Some had full-time positions or some were
consultants in pharmaceutical companies at the time of the study or in the past.
Participants who were at junior levels had at least 2 years of experience, and others had
five years of experience or more in the field of pharmacovigilance. Participant
demographics are presented in Table 2.
Table 2
Demographics of the Interviewees
Interviewees
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Experience
(In Years)
2+
15+
25+
2+
25+
20+
12+
15+
10+
15+
5+
4+
20+
4+
10+
14+
2+
10+
16+
15+
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Data Collection
Data collection was facilitated with the use of semi-structured interviews. Before
each interview began, the participants were reminded of the content of the informed
consent. They were also reminded that their participation was voluntary, that their
identity would be kept confidential, that the interview would be recorded, and that all
files and notes would be kept secured inside a locked cabinet in a private office. These
files would be destroyed after 5 years from the completion of the study.
The semi-structured interviews were expected to last 45 minutes. However, the
interviews had no time limit because each interview was highly dependent on the flow of
the conversation between me and the respondent. The entire data collection process,
included the recruitment process, pilot study, and completion of 20 interviews, lasted
twelve weeks. Data saturation was met after interviewing 20 participants in answering the
research questions of the study.
Data Analysis
The data analysis used was cross-case analysis, a method of research that allowed
the mobilization of knowledge from several case studies (Khan & VanWynsberghe,
2008). The cross-case analysis allowed for comparison of similarities and differences in
the outcome based on the interviews conducted (Maben & Penfold, 2015).
Provisional deductive codes were identified from the predetermined input, output,
and expected outcome of the two programs. These deductive codes helped in identifying
relevant inductive information concerning the program. The five deductive codes
included the following: (a) data collection, (b) use of health data, (c) active system, (d)
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voluntary reporting, and (e) systematic database. From these codes, 29 codes were
identified covering five interview questions responded by 20 participants. Eighty pages of
transcripts were read and the codes were sorted, which are presented in Appendix D.
The 29 codes that emerged from the collected data were data collection, use of
health data, active system, voluntary reporting, systematic database, privacy, relative
assessment, unexpected adverse effects, threats to public health, health safety, patientcenteredness, coincidental occurrences, risk evaluation, reporting model, post-drug
approval activities, evaluation of products, responsibility, accountability, preventive
action, alerting the public, evidence-based, vigilance, accessibility, inclusive, discovery
of new risks, other stakeholders, drug safety, opportunity to improve healthcare
professionals, and disease occurrence. For each emerging code, a meaning was
determined based on the verbatim provided by one or more participants.
For the data collection code, it was determined that FAERS and Sentinel collect
data from patients regarding the adverse effects of drugs. The sample quote from
participant 17 was:
The availability of vast volume of data which includes not only the drug reaction
details but also the information such as medical history of the patient, personal
details such as age etc. also all this information will help us derive relevant and
durable information from the data.
For the use of health data code, it was determined that health data is used for the
record of FDA. The sample quote from Participant 14 was, “There are various
organizations and to be exact I believe 18 organizations that are involved in retrieving
health data.” The Sentinel Initiative is an active system of reporting was determined for
the active system code. Participant 14 responded, “So benefits like I told you that it's an
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active system they have immediate results.” Participant 1 responded, “FAERS is
basically everything is voluntarily done most of the time it is more specific to particular
patients.” For the voluntary reporting code, it was determined that the voluntariness of
reporting is evident in the regulation. For systematic database, Participant 7 stated,
“FAERS is the FDA adverse events reporting system. It’s a database that contains the
information on Adverse events (AE’s) and medication errors” and it was determined that
the reporting the ADRs allow having a systematic database. Participant 6 stated, “I really
see here is the privacy issue- The HIPAA compliance. I don’t know if the patients would
like to share their information to a third party”, which resulted in a privacy code. It was
determined that privacy of the individuals who report adverse effects might be at stake.
Similarly for relative assessment code, it was determined that there can be differences in
how a person assesses or evaluates the effects of drugs. For the relative assessment code,
it was determined that there can be differences in how a person assesses or evaluates the
effects of drugs. Participant 8 responded:
With the FAERS system addressing adverse differential FAERS is dependent on
whether the patient really calls FDA or health care company and that one is
limited. Whereas with Sentinel the patient may be either talking to healthcare
profession that I had reaction with drug and it might get reported much more
better than the FAERS system where the patient might even not know where to
report.
For the unexpected adverse effects code, it was determined that the unexpected adverse
effects of drugs should be reported in order to be prevented. Participant 12 responded,
“There would be more clinical information available regarding the adverse effect and
what was happening so that would be one major benefit”. Participant 2 mentioned, “I say
society it means all the players who are responsible for managing healthcare in the
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system.” It was determined that the adverse effects of drugs pose threats to public health
which led to the threats to public health code. Health safety of patients can be achieved if
drugs are safe was determined for the health safety code as Participant 2 stated, “The
potential benefits of the patients ultimately the FDA was created to benefit the patients
and consumers and the larger population will be benefited by this and more genotyping
and genomics data.” For the patient-centeredness code, it was determined FAERS and
Sentinel Initiative are focused on the welfare of patients. Participant 20 stated:
I think it’s mostly patients safety, they are having a lot of information sharing it
they are able to share it, they are compiling they are getting a great deal more info
on all these products hopefully to be used for a patient safety.
Coincidental occurrences on patients that do not have direct correlation to the drugs
might be mistaken as adverse drug effects that were determined for the coincidental
occurrences code. Participant 2 stated:
I can confirm it if you like all the adverse reactions that happened whether it was
on doctors clinic or it happened anywhere else in the hospital only 6-10% were
reported since the institution established FAERS whereas the sentinel program
because it is not asking you report anything it is asking you to just keep your data
in a particular format.
For the risk evaluation code, it was determined that the risks on drugs will properly be
assessed if there is a proper reporting model. Participant 13 stated:
I think the challenges are that you know with a lot of data you also comes with it
is noise and you know the quality of data and probably you can have where
signals will get lost and then you have different interpretations of signals of what
is actually a risk and what is I think it gets a little bit murky with that large
amount of data.
The reporting model of how adverse drug effects are recorded should be systematic is
determined for the reporting model code. Participant 5 stated, “It doesn’t seem that they
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have a separate method they can use to overcome under reporting of worst events so if
the data is not there they can obtain any additional information.” Post-drug approval
activities must be evaluated to ensure the safety of the public was determined for the
post-drug approval activities code. Participant 4 stated:
So basically they use all these query methods so that they can query these large
database to determine to get the desired results of what are on what features are
they looking for and what kind of problems they want to solve or especially what
drug they want to improve.
The proper evaluation of products should be the priority in order to ensure health safety
was determined for the evaluation of products code. Participant 18 stated, “Evaluation is
done principally by FDA and they will be the one who will analyze the data and gather
critical information out of this.” For the responsibility code, it was determined that there
should be a government agency that regulates drugs in order to monitor responsibility on
the safety of drugs. Participant 20 stated, “So here again I think the agency has the
ultimate responsibility when it comes to reporting though in general it is on … it’s on the
health care professionals and consumers.”
For the accountability code, it was determined that there should be a government
agency that regulates drugs in order to monitor accountability on the safety of drugs.
Participant 17 stated, “Again the FDA, the stakeholders are solely responsible for
implementing and evaluating these methods.” Participant 13 stated, “I think there are may
be 18 organizations collecting this data help data warehousing and ensure companies like
that have access to vast of data and vast of health data.” The reporting model is a form of
preventive action to ensure that future similar incidents will be prevented which was
determined for the preventive action. For the alerting the public code, it was determined
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that the public has the right to know on the possible adverse drug effects based on the
experience. Participant 17 stated:
The potential challenges which I am looking upon in this under reporting of
adverse from these methods is to instill a sense of security amongst the patients
and we have to educate them that their personal data is only used for medicinal
and research purposes. The meaning for evidence-based code was determined as
the reporting of adverse drug effects by the patients will allow evidence-based
conclusions.
Participant 19 stated, “Doctor must have prescribed something and there must be some
evidence and records they don’t have to wait for many years.” Vigilance in the
pharmaceutical industry must be improved was determined for the vigilance code.
Participant 16 stated, “I mean all the stake holders that are involved should be responsible
whether be the manufacturers or the distributors or the FDA or the healthcare
professionals or even the patient.” For the accessibility code, it was determined that the
records and data collected should be made accessible to the public. Participant 16 also
stated, “Information is generally documented within the healthcare providers database it’s
more readily accessible to FDA to perform to better evaluate the data.” For the inclusive
code, it was determined that a more inclusive system should be created so that the
development will go beyond research purposes. Participant 5 responded, “To obtain
extensive stakeholders and partners to participate in this imitative there will have to some
kind of method to educate consumer for this work so that they may be able to share their
health care info to the database.” It was determined that new risks on the adverse drug
effects will be prevented for discover of the new risks code. Participant 4 stated:
That it can eliminate under reporting to extent but it will be still be there because
the access to data is small and I think they are also working on it once data bases
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are linked and they have access to those databases then they will have better
analysis to problems of adverse drug reactions.
Participant 5 stated, “Consumer may not allow releasing their health care info and they
need to increase their stakeholders if they want to expand and implement all over the
country.” It was determined that a more inclusive progress in the field of
pharmacovigilance is possible if there are more stakeholders that led to the other
stakeholder’s code. For the drug safety code, it was determined that drug safety should be
prioritized in ensuring that there are proper reportorial mechanisms. Participant 17 stated,
“It will help derive the FDA and to evaluate about a drug and take some safety measures
about a drug.” For the opportunity to improve healthcare professionals code, it was
determined that healthcare professionals will improve their performance if the drugs are
properly regulated. Participant 5 stated, “So the challenge again would be the lack of
partnership, they have to increase their partnership to all physicians, pharmacies in order
to expand their data base.” Lastly for the disease occurrence code, it was determined that
disease occurrence can be lessened if there is proper regulation of drugs available in the
market. Participant 19 stated, “There are some other diseases and other things that I have
and if I am going to take this medication it going to have an impact on me.”
As codes emerged in the transcripts, I reviewed and categorized these codes for
further analysis. Out of the 29 codes, I identified six categories. These were: data
collection, patient’s health, regulatory mechanism, preventive measure, other
stakeholders, and drug manufacture. For the first category, the associated codes for data
collection were data collection, use of health data, active system, voluntary reporting,
systematic database, privacy, and relative assessment. The meaning was determined
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based on associated codes derived from participant’s response. The meaning from first
category was determined as FAERS and Sentinel Initiative provide a systematic data
collection for a database that would use health data to improve public health. For the
second category, the associated codes for patient’s health were unexpected adverse
effects, threats to public health, health safety, patient-centeredness, and coincidental
occurrences. The meaning from second category was determined as the adverse effects of
drugs will be recognized and the safety of the patients and the public will be prioritized.
For the third category, the associated codes for regulatory mechanism were risk
evaluation, reporting model, post-drug approval activities, and evaluation of product
responsibility and Accountability. The meaning was determined as the reporting model
provides a regulatory mechanism after the drug approval activities in order to evaluate
the medicinal products. For the fourth category, the codes for preventive measure were
preventive action, alerting the public, and evidence-based vigilance. The meaning derived
from this category and associated event was the presence of FAERS and Sentinel
Initiative improves the vigilance of the public towards the adverse effects of drugs. The
fifth category, other stakeholder were based on codes such as accessibility, inclusive,
discovery of new risks, and other stakeholders. The meaning determined from these
codes and category was a more inclusive database will include other stakeholders and
make the records more accessible. The sixth category was drug manufacture which was
based on codes such as drug safety, opportunity to improve health care professionals, and
disease occurrence. The meaning derived from these codes and category was the
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availability of a surveillance system such as FAERS and Sentinel Initiative will improve
drug safety.
Themes were derived from analyzing the responses of the participants in the
interviews. Each interview was thoroughly read and analyzed. The codes were created
based upon analyzing each interview session. The cross-case analysis was conducted by
analyzing the codes derived per interviewee. Twenty nine codes were derived and these
codes were divided into six categories. These themes are further discussed in the latter
part of the chapter.
Evidence of Trustworthiness
The results of the study were credible and dependable. The interviews verbatim
were transcribed so as not to avoid misinterpretation or poor recall of the answers
provided by the participants. It was also confirmed from the audio whenever there were
ambiguous content within the transcripts of the interview. To ensure dependability, it was
ensured an audit trail that was available for peers to review. The names of the participants
were maintained confidential. This improved that trustworthiness of the study, because
revealing the identities of the participants might hamper their intent to be open and
prudent in providing the information for the research. The transcripts used for the study
were faithful to the original interviews conducted with the participants.
Thomas and Magilvy (2011) claimed the association between transferability and
external validity. Transferability involved the study’s ability to transfer findings to
another population different from the one used by the researcher of the original study
(Thomas & Magilvy, 2011). Hospitals could benefit from the study and ensured that
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ADRs were reported. The demographic profile of the interviewees indicated that the
study would have similar results when a different set of pharmacovigilance experts were
interviewed. The external validity of the study was ensured by the strict scrutiny of the
data collected from the interview. To ensure transferability of the study, the audio files
were promptly recorded of the interview and the verbatim transcript. Pseudonyms, known
to the researcher alone were used to replace all these identifying information to ensure the
confidentiality of the participants. The snowballing techniques were utilized and I met
different people who worked in pharmacovigilance department. The participants who
agreed to participate in the study had self-reported knowledge of Sentinel initiative.
These participants worked closely in drug safety department of pharmaceutical
companies. Hence, they had work closely with FAERS.
Results
Based on the analysis of the codes and categories, theme 1 emerged, “The
presence of FAERS and Sentinel Initiative improves the vigilance of the public towards
the adverse effects of drugs and promotes health and public safety.” This theme was
reflected from the following categories: Patient's health; preventive measure; drug
manufacture; and, other stakeholders. The first theme was derived from 52 responses. For
this theme, 52 was the sum of the total responses from the codes where this theme
emerged from. The second theme showed that, “FAERS and Sentinel Initiative provide a
systematic data collection for a database that would use health data to improve public
health.” This theme was reflected from the category of data collection and gathered 28
responses. For this theme, 28 responses was the total of the responses to the codes where
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this theme emerged from. The third theme showed that, “The reporting model provides a
regulatory mechanism after the drug approval activities in order to evaluate the medicinal
products.” This theme was attained from 22 responses. To summarize, the following were
the themes of the study:
Theme 1. The FAERS and Sentinel Initiative improve the vigilance of the public
towards the adverse effects of drugs and promote health and public safety.
Theme 2. FAERS and Sentinel Initiative provide systematic data collection for a
database that would use health data to improve public health.
Theme 3. The reporting model provides a regulatory mechanism after the drug
approval activities in order to evaluate the medicinal products.
The three themes will be further discussed below and codes and categories
associated with the themes can be found in Appendix E. More comprehensive
information on the responses of the participants was shown in Appendix D (Emerging
Codes and Categories).
Theme 1. The presence of FAERS and Sentinel Initiative improves the vigilance of
the public towards the adverse effects of drugs and promotes health and public
safety.
Patient’s Health. The maintenance of patient’s health was the priority in every
surveillance mechanism that promoted the monitoring of the adverse effects of drugs.
There were some instances where the performance in pharmacovigilance could be
improved from the current set up of FDA’s Sentinel. There was a possibility of tracking
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back the results and effects of a certain drug and medication so that it could be
comprehensively studied and researched on. As suggested by Participant 15:
See the benefits can be really big and the reason why I say that if you look
at the data reporting this not even ten years back I would suggest 5 years
back for every year you see there are so many challenges and the changes
that we are coming across in lifestyle and day to day activities which leads
somewhere towards the pharmaceutical companies and that is where they
are able to do all this new medications and launch all these drugs but at the
same time behind the scenes somewhere cumulative data is helping them
to take the proactive initiative.
The awareness of the people and the patients should be improved in order to increase the
effectiveness of the Sentinel surveillance system. With the awareness that data could be
accessed to inquire about certain information on the effects of medication, the patients
would become proactive in interacting with the doctors. The patients would be more
informed with the advice that they derive from their physicians. As observed by
Participant 4:
So like I told you earlier people were not aware about these portals and
reporting of various drug problem since it’s a common interaction between
the doctor and the patient so its take care of the under reporting and all
these database are linked in sentinel so they will have access to data in
terms of determining what all adverse reaction can be caused by a drug.
Unexpected adverse effects. The unexpected adverse effects of drugs
should be reported in order to be prevented. Quoting Participant 12, “There would
be more clinical information available regarding the adverse effect and what was
happening so that would be one major benefit.” According to Participant 3, “it
addresses underreporting; just because somebody had something happened.”
According to Participant 18, “Benefits are as discussed for FAERS only the
extremely adverse events get reported.”
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Threats to public health. According to Participant 2, “I say society it means all
the players who are responsible for managing healthcare in the system.” The adverse
effects of drugs pose threats to public health. According to Participant 1, “Then we also
have issue with health plan if there is like common center dealing with all these
information.”
Health safety. According to Participant 1, “it will help them to reduce safety
issues that what we have and they could help with prescribing activities and it all helps
the healthcare system in itself.” Participant 2 likewise mentioned, “The potential benefits
of the patients ultimately the FDA was created to benefit the patients and consumers and
the larger population will be benefited by this and more genotyping & genomics data.”
Health safety of patients can be achieved if drugs are safe.
Patient-centeredness. According to Participant 5, “Sentinel because if the data
info collected on patients through insurance companies.” Quoting Participant 20, “I think
it’s mostly patients safety, they are having a lot of information sharing it they are able to
share it, they are compiling they are getting a great deal more info on all these products
hopefully to be used for a patient safety.” FAERS and Sentinel Initiative are focused on
the welfare of patients.
The FAERS and Sentinel Initiative were forms of surveillance that attempted to
enance the vigilance of the public towards responsible data collection on the adverse
effects of drugs. Participant 17 was quick to note the importance of data collection
because the availability of data was relevant to have durable information which could
help in the advancement of health. An active system of data collection allowed immediate
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results. The voluntariness of reporting was also a positive factor to ensure that adverse
drug reactions were protected. The accuracy of the information and the speed of
obtaining information were some of the benefits that could be derived from Sentinel
Initiative. As the more proactive surveillance mechanism, Participant 14 said that:
Benefits will be the speed of obtaining information and the accuracy of the
information being reported. What I understand from the system, it seems
that there is some confusion, chances are that you will have to go to the
source that has provided the information.Going to the source that has
provided the information, it will be one or two people; instead of going to
the whole range of people that are involved even. Even though it’s a new
way of collecting the AE [adverse events], this might be a speedy process.
Negative factor- it might be I am not 100 % sure it might have effect
pharmaceutical companies.
Preventive Measure. The data available using the surveillance methodologies in
the field of pharmacy should be more inclusive and open to the public. It should be
emphasized that the main reason behind the data collection of ADRs was to ensure that
future negative effects would be prevented.
Preventive action. The reporting model was a form of preventive action to ensure
that future similar incidents would be prevented. Quoting Participant 13, “I think there
are may be 18 organizations collecting this data help data warehousing and ensure
companies like that have access to vast of data and vast of health data.” The purpose of
Sentinel and FAERS should go beyond mere research. The awareness of the public
should be increased by making the data available to third parties, thus enhancing the
vigilance of drug users. As pointed out by Participant 6:
Since the data is mentioned by those organizations or plans, and at this point only
FDA is accessing this data, only FDA is approved for accessing the data so it is
really not true data for drug safety purposes, and FDA using it for the lack of any
other method out there for using this system, so that I would call it a challenge,
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when we have that anybody can access that data space, where anybody can access
and get information about a potential drug reaction and so on. That day is far
away. Even after all they say that Sentinel system is augmented FAERS system,
we still have that challenge out there.
Alerting the public. According to Participant 4, “So like I told you earlier people
were not aware about these portals and reporting of various drug problems since it’s a
common interaction between the doctor and the patient.” Participant 17 noted that, “The
potential challenges which I am looking upon in this under reporting of adverse from
these methods is to instill a sense of security amongst the patients and we have to educate
them that their personal data is only used for medicinal and research purposes.” The
public has the right to know on the possible adverse drug effects based on the experience
of others.
Evidence-based. The reporting of adverse drug effects by the patients will allow
evidence-based conclusions. Quoting Participant 19, “Doctor must have prescribed
something and there must be some evidence and records they don’t have to wait for many
years.”
Vigilance. Participant 16 mentioned that, “I mean all the stakeholders that are
involved should be responsible whether be the manufacturers or the distributors or the
FDA or the healthcare professionals or even the patient.” Vigilance in the pharmaceutical
industry must be improved. Participant 17 was quick to note the importance of data
collection because the availability of data was relevant to have durable information which
could help in the advancement of health.
Drug Manufacturer. The FAERS surveillance system was beneficial in
pharmacovigilance because it monitored the adverse reactions to drugs and medication.
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Monitoring the adverse reactions added to the information available to the public domain.
The public and the patients benefit from the surveillance systems. The patients were now
more informed about the consequences of the medicines that they take. The
pharmaceutical companies and health agencies also benefitted from the reports. The
pharmaceutical companies would become more vigilant in ensuring that the products are
safe. Because of the mechanism to report and self-report the adverse reactions, the
companies that manufacture drugs would now be more careful in the advancement of the
safety of the medicine. The use of health data was one of the advantages in the use
FAERS. Health data that was voluntarily given to the FDA could create an awareness to
the general public. The availability of the information that could readily be accessed by
the public was one of the benefits of the FAERS.
Drug safety. According to Participant 17, “It will help derive the FDA and to
evaluate about a drug and take some safety measures about a drug.” Drug safety should
be prioritized in ensuring that there were proper reportorial mechanisms.
Opportunity to improve healthcare. Quoting Participant 5, “So the challenge
again would be the lack of partnership, they have to increase their partnership to all
physicians, pharmacies in order to expand their data base.” Healthcare professionals
would improve their performance if the drugs were properly regulated.
Disease occurrence. Disease occurrence could be lessened if there was proper
regulation of drugs available in the market. Participant 19 noted that, “There are some
other diseases and other things that I have and if I am going to take this medication it
going to have an impact on me.”
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Other Stakeholders. The scope of the Sentinel Initiative could be enhanced.
More stakeholders should be considered. The presence of more stakeholders would make
the benefits and advantages of the policies more comprehensive and encompassing. The
awareness of the people about these surveillance systems should be enhanced. The selfreporting requirements should be more active. More people should be able to access the
information. The information collected should not be limited for research purposes but
should actually include having relevance to the general public.
According to Participant 5, there was a need to obtain more stakeholders to
improve the performance in the reportorial requirements. It could be said that the
inclusion of more stakeholders would make the drug companies more proactive because
more interested parties would be affected by their actions:
They will need to obtain more stakeholders so I don’t think they have a
method to handle the under reporting of drug reactions so it doesn’t seem
that they have a separate method they can use to overcome under reporting
of worst events so if the data is not there they can obtain any additional
information.
Accessibility. Participant 5 noted that, “Consumer may not allow releasing their
health care info and they need to increase their stakeholders if they want to expand and
implement all over the country.” A more inclusive progress in the field of
pharmacovigilance was possible if there were more stakeholders.
Inclusive. It was noted by Participant 5 that, “To obtain extensive stakeholders
and partners to participate in this initiative there will have to some kind of method to
educate consumer for this work so that they may be able to share their health care info to
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the database.” A more inclusive system should be created so that the development would
go beyond research purposes.
Discovery of new risks. New risks on the adverse drug effects would be
prevented. As mentioned by Participant 4, “That it can eliminate under reporting to extent
but it will be still be there because the access to data is small and I think they are also
working on it once data bases are linked and they have access to those databases then
they will have better analysis to problems of adverse drug reactions.”
To summarize, it could be concluded that the adverse effects of drugs would be
recognized and the safety of the patients and the public would be prioritized. The
presence of FAERS and Sentinel Initiative improved the vigilance of the public towards
the adverse effects of drugs. A more inclusive database would include other stakeholders
and make the records more accessible. The availability of a surveillance system such as
FAERS and Sentinel Initiative would improve drug safety.
Theme 2. FAERS and Sentinel Initiative provide a systematic data collection for a
database that would use health data to improve public health.
The FAERS was beneficial because it was a form of data collection that was
based on the voluntary reporting of individuals, patients or physicians that suffered from
ADRs. It was beneficial because the patients voluntarily report the data and not based on
compulsory requirements mandated by regulations. Further, the FAERS surveillance
system allowed the pulling out of the market, the drugs that were proven to be
detrimental to the health of the public.
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Data collection. Participant 17 noted that, “The availability of vast volume of data
which includes not only the drug reaction details but also the information such as medical
history of the patient, personal details such as age etc. also all this information will help
us derive relevant and durable information from the data.” FAERS and Sentinel collected
data from patients regarding the adverse effects of drugs.
Use of health data. Health data was used for the record of FDA. According to
Participant 14, “There are various organizations and to be exact I believe 18
organizations that are involved in retrieving health data.”
Active system. The Sentinel Initiative was an active system of reporting. As
observed by Participant 4, “So benefits like I told you that it's an active system they have
immediate results.” According to Participant 17, “Benefits will be the speed of obtaining
information, the accuracy of the information being reported and there seem for what I
understand from the system there seem that if there is some confusion.”
Voluntary reporting. The voluntariness of reporting was evident in the regulation.
According to Participant 1, “FAERS is basically everything is voluntarily done most of
the time it is more specific to particular patients.” According to Participant 6, “All those
drug adverse reports either directly send to FDA or they are sent by the manufactures to
FDA are entered in FAERS. The biggest issue here in this whole exercise is that reporting
a drug adverse reaction is not required by law or anyone else but it’s an voluntary basis
exercise.”
Systematic database. Quoting Participant 7, “FAERS is the FDA adverse events
reporting system. It’s a database that contains the information on adverse events (AEs)
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and medication errors.” Reporting the adverse drug reactions allowed having a present
systematic database. According to Participant 4, the Sentinel initiative, “That it can
eliminate under reporting to extent but it will be still be there because the access to data is
small and I think they are also working on it once data bases are linked and they have
access to those databases then they will have better analysis to problems of adverse drug
reactions.”
Privacy. Privacy of the individuals who reported adverse effects might be at stake.
According to Participant 6, “I really see here is the privacy issue- the HIPAA compliance.
I don’t know if the patients would like to share their information to a third party.”
Participant 5 mentioned that, “Adherence to privacy laws, consumer may not allow to
release their health care info and they need to increase their stakeholders if they want to
expand and implement all over the country.”
Relative assessment. There could be differences in how a person assessed or
evaluated the effects of drugs. According to Participant 8:
With the FAERS system addressing adverse differential FAERS is dependent on
whether the patient really calls FDA or health care company and that one is limited.
Whereas with Sentinel the patient may be either talking to healthcare profession that I
had reaction with drug and it might get reported much more better than the FAERS
system where the patient might even not know where to report.
The Sentinel could be a great help in ensuring that all adverse reactions to a drug were
reported. It was to be noted that underreporting must be discouraged because failure to
notify the FDA regarding certain instances may pose danger to the lives of future users of
the medication. Participant 17 further noted that:
Sentinel Initiative address uneven quality of adverse drug reactions reports
compared to FAERS just like in FAERS is a voluntary system where in
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the patients report themselves about a serious suspected drug reaction and
information can be limited so it can be difficult for the FDA to decide
whether an adverse reaction is serious or not and it can be difficult for the
FDA to take some safety measures against the drug.
The FAERS surveillance methodology was perceived to be a passive
methodology. This was contrasted with the capability of the FAERS wherein there was a
less number of population reached. According to Participant 6, the Sentinel surveillance
methodology was an improved way of collecting data because it was more active as it
was highly imposed and regulated:
Per the latest estimate, there are about 18 organizations participating and
FDA can access the medical data of almost 178 million patients through
this initiative. Since the data is maintained by the organizations/plans
using a common data model, it’s an example of distributed database. This
system is available to FDA only for monitoring the post-marketing
product safety information. A query is entered into the system and FDA
can have the information from this vast data of 178 million patients on
need basis. Because of the nature of information retrieved from this vast
data, the Sentinel initiative is so called “active” system. Why I’m calling it
“Active” because the data is coming from HMOs plans, hospitals, and
other medical centers where the data is entered by the health care
professional while they are consulting or treating a patient. So I would say
that the Sentinel initiative is augmented the FAERS system.
The same participant was of the observation that the Sentinel was better in terms of data
collection and was a far cry from the passive FAERS system where compliance seemed
to be optional, “All those drug adverse reports either directly send to FDA or they are
sent by the manufactures to FDA are entered in FAERS. The biggest issue here in this
whole exercise is that reporting a drug adverse reaction is not required by law or anyone
else but it’s an voluntary basis exercise.”
To summarize the second theme, it could be inferred that FAERS and Sentinel
Initiative provided a systematic database that would use health data to improve public
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health. Having a systematic mode of data collection would allow the careful sorting of
what was relevant and what was not. Data collection of adverse drug effects would also
help in research and prevention of ADRs in the future.
Theme 3. The reporting model provides a regulatory mechanism after the drug
approval activities in order to evaluate the medicinal products.
The FAERS and Sentinel Initiative provided a good regulatory mechanism
because the FDA would have access to vital information to monitor and evaluate the
adverse effects of drug products. One of the challenges in FAERS was that it was a mere
passive way of reporting data to the FDA. Underreporting was prevalent in the FAERS
system because of the lack of mechanisms to ensure that each ADR is brought to the
attention of the FDA. According to Participant 7, there are many challenges to the current
FAERS:
The current FAERS system doesn’t have a good picture, there is not
necessarily a good population size and not an easy way to interpret the
data with the advanced analysis. So for the electronic healthcare data
source, we will be tracking millions of patients and will also contain more
comprehensive and complete information for the patients that are in the
system. We will maximize the efficiency of the risk identification system,
and also the incidents of reporting will be detectable and accurate.
The access to data in the FAERS system was also a challenge. Scientists of the FDA were
not able to access the reports reported to FAERS on a real time basis. This posed great
threats to the safety of the public when the data could not be divulged to the public in a
prompt manner. As observed by Participant 10:
As I said earlier, scientists will have capabilities to find the answers to
some of their questions in weeks, which with the FAERS systems used to
take months or sometimes even longer, so that’s one of the benefits I see.
With that it will hub that to go towards right research, not like they did
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research for 5 years and then figure out okay, this is not going to help. So
probably getting the right kind of remediation, I don’t have the right word
but finding right resolutions for particular health problems I think this
system would help.
Sentinel Initiative and FAERS had challenges and negative impacts because of lack of an
effective and efficient regulation to ensure that the purpose was served. There was lack of
responsibility in the implementation and evaluation.The rules should be more specific in
pointing out the certain responsibilities and accountability of the different government
agencies such as the FDA. The data collected might not be valuable for the human public
because it was not accessible. There could be an issue of privacy in the reporting
requirements. As in other policies, the issue of privacy in the reporting of adverse impacts
could be a major concern of patients and other affected individuals.
One disadvantage of the Sentinel Program was the lack of responsibility in the
implementation and evaluation. There was a system of notification but the liability of the
drug companies was not clear. There was no system of going to the next step once the
effects of notifcation had been sent to the FDA. As pointed by Participant 19:
An international body that‘s like they call it an international conference on
humanizations and then they came up with the guidelines and that
guidelines helped us to build that system, the FDA adversary reporting
system. The one is based on the guidelines and in that FAERS the
manufacturers is responsible to notify as the drug is out in the market they
just have to notify the market if there is any event related to that drug.
A challenge posed in the evaluation of the methhods in FDA Sentinel was the fact that
the data collected might not be collected for research purposes. There was a need to
ensure that the validity of the coding would be maintained. According to Participant 11,
the FDA should be responsible in the implementation of the methods in this policy
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because “they need all that information to make the assessment and to approve or
disapprove you know drugs on the market so they should want to have the best
surveillance system out there.” The following explained the different codes associated to
this formed theme:
Risk evaluation. Participant 13 mentioned that, “I think the challenges are that
you know with a lot of data you also comes with it is noise and you know the quality of
data and probably you can have where signals will get lost and then you have different
interpretations of signals of what is actually a risk and what is I think it gets a little bit
murky with that large amount of data.” The risks on drugs would properly be assessed if
there was a proper reporting model.
Reporting model. Participant 5 noted that, “It doesn’t seem that they have a
separate method they can use to overcome under reporting of worst events so if the data
is not there they can obtain any additional information.” The reporting model of how
adverse drug effects were recorded should be systematic. As mentioned by Participant 17,
“The sentinel would help make the data more reliable removing the underreporting of
several adverse drug reactions by it will flood the data with records which people earlier
used to think may be irrelevant or not necessary and sufficient to be reported.”
Post-drug approval activities. According to Participant 4, “So basically they use
all these query methods so that they can query these large database to determine to get the
desired results of what are on what features are they looking for and what kind of
problems they want to solve or especially what drug they want to improve.” Post-drug
approval activities must be evaluated to ensure the safety of the public.
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Evaluation of products. The proper evaluation of products should be the priority
in order to ensure health safety. According to Participant 18, “Evaluation is done
principally by FDA and they will be the one who will analyze the data and gather critical
information out of this.” Participant 9 mentioned that there could be regional restrictions
for the study itself because the usage of the drug could be much wider in region than
compared to other regions.
Responsibility. There should be a government agency that regulates drugs in order
to monitor responsibility on the safety of drugs. Participant 20 mentioned, “So here again
I think the agency has the ultimate responsibility when it comes to reporting though in
general it is on … it’s on the health care professionals and consumers.”
The relativity of determining whether a certain effect was adverse or not was a
consideration that posed challenge to the effectiveness of the Sentinel surveillance policy.
Participant 9 mentioned that there could be regional restrictions for the study itself
because the usage of the drug could be much wider in region than compared to other
regions. The funds were also challenges to the methods of reporting. According to
Participant 2:
What you call adverse reaction may not be adverse reaction historically
the away FDA has taken the stance like sometimes because they are free
to report it o media they are free to report it to pharma company they are
free to create out a norm that you to have to pull out the drug from the
market these are the sensitive thing so its is up to the pharma companies to
take a stance and really help FDA to understand or keep a list of things I
am just simplifying things a little bit but these are the risks.
As in any program or policy, the issue of privacy was a big consideration in determining
the impact and challenges to a specific program. According to Participant 7, the privacy
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of the patients could also be compromised with the new reportorial requirements. Privacy
concerns were also raised by Participant 5:
So right now there is limited data source and have 17 partners right now
and to this be able to work they will have to expand and their data sources
to a great deal, funding will be another challenge, adherence to privacy
loss, consumer may not allow to release their health care info and they
need to increase their stakeholders if they want to expand and implement
all over the country and internationally as worse event and signal
collection is worldwide just the USA , right now the sentinel would be
limited USA.
There was a need to include more organizations to cooperate with the Sentinel Initiative.
Currently, there were only 18 organizations that were part of this policy. According to
Participant 12, “So one of the major disadvantages or challenges that have been referred
to that I see is that there are only 18 organizations that are currently involved so I feel like
that would limit the sentinel initiative so there need to be more organization that need to
be involved I feel to deal with this challenge.” There was a need to focus on including
more organizations so that the data collected by FDA would be more comprehensive and
the information made available to the public would be more complete and relevant.
To summarize the third theme, it could be concluded that the presence of a
reporting model provided a regulatory mechanism after the drug approval activities in
order to evaluate the medicinal products. A regulatory mechanism would decrease the
voluntariness of reporting and allow a more systematic way of monitoring the adverse
drug effects. Further, the regulatory mechanism would hold a specific government
agency accountable for the evaluation of the effects of drugs.
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Responses to the Research Questions
RQ1. The results of the study answered the three research questions originally
posed. The first research question asked the prospective benefits of the FDA's Sentinel
Initiative as compared with the FAERS surveillance methodology. Sentinel Initiative and
FAERS were beneficial in pharmacovigilance because they monitored the adverse
reactions to drugs and medication. Monitoring the adverse reactions added to the
information available to the public domain. The public and the patients benefitted from
the surveillance systems. The patients were now more informed about the consequences
of the medicines that they took. The pharmaceutical companies and health agencies also
benefitted from the reports. The pharmaceutical companies would become more vigilant
in ensuring that the products were safe. Because of the mechanism to report and selfreport the adverse reactions, the companies that manufacture drugs would now be more
careful in the advancement of the safety of the medicine.
The Sentinel could be a great help in ensuring that all adverse reactions to a drug
were reported. As mentioned by Participant 17, “The sentinel would help make the data
more reliable removing the underreporting of several adverse drug reactions by it will
flood the data with records which people earlier used to think may be irrelevant or not
necessary and sufficient to be reported.” As a more active way of getting information to
monitor adverse drug effects, Sentinel Initiative promised a more reliable source of data
available for the public and for pharmaceutical companies. Further, the Sentinel Initiative
was a more inclusive way of providing information to the public.
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The FAERS surveillance methodology was perceived to be a passive
methodology. As observed by Participant 9, the capturing of data in Sentinel was more
proactive and real time data was collected. The same participant was of the observation
that the Sentinel was better in terms of data collection and was a far cry from the passive
FAERS system where compliance seemed to be optional, “All those drug adverse reports
either directly send to FDA or they are sent by the manufactures to FDA are entered in
FAERS.” In FAERS, it can be said that there was already accountability on the part of
FDA.
RQ2. The second research question asked the challenges and negative impacts of
the FDA's Sentinel Initiative as compared with the FAERS surveillance methodology.
Sentinel Initiative and FAERS had challenges and negative impacts because of lack of an
effective and efficient regulation to ensure that the purpose was served. There was lack of
responsibility in the implementation and evaluation. The rules should be more specific in
pointing out the certain responsibilities and accountability of the different government
agencies such as the FDA. The data collected might not be valuable for the human public
because it was not accessible. There could be an issue of privacy in the reporting
requirements. As in other policies, the issue of privacy in the reporting of adverse impacts
could be a major concern of patients and other affected individuals.
One disadvantage of the Sentinel Program was the lack of responsibility in the
implementation and evaluation. The relativity of determining whether a certain effect was
adverse or not, was a consideration that posed challenge to the effectiveness of the
Sentinel surveillance policy. Participant 9 mentioned that there could be regional
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restrictions for the study itself because the usage of the drug could be much wider in
region than compared to other regions.
RQ3. The third research question asked the lessons learned that could enhance the
scope of the Sentinel Initiative. The scope of the Sentinel Initiative could be enhanced.
More stakeholders should be considered. The presence of more stakeholders would make
the benefits and advantages of the policies more comprehensive and encompassing. The
awareness of the people about these surveillance systems should be enhanced. The selfreporting requirements should be more active. More people should be able to access the
information. The information collected should not be limited for research purposes but
should actually include having relevance to the general public. There were some
instances where the performance in pharmacovigilance could be improved from the
current set up of FDA’s Sentinel. There was a possibility of tracking back the results and
effects of a certain drug and medication so that it could be comprehensively studied and
researched.
Inclusion of more stakeholders. The scope of the Sentinel Initiative could be
enhanced. More stakeholders should be considered. The presence of more stakeholders
would make the benefits and advantages of the policies more comprehensive and
encompassing. The awareness of the people about these surveillance systems should be
enhanced. The self-reporting requirements should be more active. More people should be
able to access the information. The information collected should not be limited for
research purposes but should actually include having relevance to the general public.
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More active self-reporting requirements. The reporting model of how adverse
drug effects were recorded should be systematic. Post-drug approval activities must be
evaluated to ensure the safety of the public. The requirements to report must be more
stringent. The information must be used by the FDA to improve data collection and
establish a safer method of drug manufacture. As mentioned by Participant 17, “The
sentinel would help make the data more reliable removing the underreporting of several
adverse drug reactions by it will flood the data with records which people earlier used to
think may be irrelevant or not necessary and sufficient to be reported.”
Summary
There were various reasons why FAERS and Sentinel Initiative were effective
surveillance methodologies to enhance pharmacovigilance. The Sentinel could be a great
help in ensuring that all adverse reactions to a drug were reported. The availability of the
information that could readily be accessed by the public was one of the benefits of the
FAERS. On the other hand, the accuracy of the information and the speed of obtaining
information were some of the benefits that could be derived from Sentinel Initiative.
While there are benefits and advantages, there were also challenges related to the
implementation of either FAERS or Sentinel Initiative. One disadvantage of the Sentinel
Program was the lack of responsibility in the implementation and evaluation. There was a
system of notification but the liability of the drug companies was not clear. A challenge
posed in the evaluation of the methods in FDA Sentinel was the fact that the data
collected may not be collected for research purposes. There was a need to ensure that the
validity of the coding would be maintained. As in any program or policy, the issue of
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privacy was a big consideration in determining the impact and challenges to a specific
program. There was a need to include more organizations to cooperate with the Sentinel
Initiative.
There was a need to enhance the scope of Sentinel Initiative to make it a more
effective way of surveillance for pharmacovigilance. It could be said that the inclusion of
more stakeholders would make the drug companies more proactive because more
interested parties would be affected by their actions. The awareness of the people and the
patients should be improved in order to increase the effectiveness of the Sentinel
surveillance system. With the awareness that data could be accessed to inquire about
certain information on the effects of medication, the patients would become proactive in
interacting with the doctors. The data available using the surveillance methodologies in
the field of pharmacy should be more inclusive and open to the public. This would ensure
that the welfare of all the stakeholders in the pharmaceutical industry would be protected.
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Chapter 5: Discussion
The current FDA consumer safety surveillance system used FAERS for reporting
adverse events involving pharmaceutical drugs (FDA, 2012a; Powers & Cook, 2012).
The FAERS used a database designed to assist the FDA and its partners in monitoring
postmarketing safety of approved drugs and other biologic products (Powers & Cook,
2012). However, the FAERS had limitations such as not reporting real-time data
collection (FDA, 2012a). Therefore, the FDA launched the Sentinel Initiative in 2008.
The FAERS and Sentinel Initiative were adverse drug reaction (ADR) reporting systems.
This study addressed the lack of research regarding the impact of Sentinel Initiative
compared to the FAERS. It was necessary to assess the benefits and challenges associated
with the FDA’s Sentinel Initiative compared to the current FAERS surveillance
methodology.
According to the FDA (2012a), the FAERS had (a) a system for reporting the
adverse effects of drugs, and (b) a database for these reported cases of ADRs. The
Sentinel Initiative was a national electronic system for monitoring the safety of FDAapproved drugs and other medical products (FDA, 2012d). The Sentinel system was
developed and implemented as an aid to the existing FAERS. The FAERS did not make
use of real-time data, which referred to the precise time or location that a drug was used
or consumed by the market members (Gottlieb, 2005). Presently, the reporting system
used by the FAERS was voluntary and quarterly (Powers & Cook, 2012). Instead of
depending on point-of-care data collection, the Sentinel Initiative could access multiple
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existing data systems such as electronic health record systems and medical claims
databases (Platt et al., 2009).
The purpose of this qualitative comparative case study was to examine the
FAERS surveillance system and the FDA’s Sentinel Initiative to determine the benefits
and consequences of the Sentinel Initiative in terms of drug consumer safety. This
qualitative study included the perceptions of individuals who had worked closely with
FAERS program and were aware of the Sentinel Initiative. I interviewed key informants
who worked with FAERS andwere familiar with the Sentinel Initiative to better
understand their perceptions of the differences between these two programs.
The results of the study answered the three research questions originally posed.
The first research question addressed the prospective benefits of the FDA’s Sentinel
Initiative as compared with the FAERS surveillance methodology. Both programs were
beneficial in pharmacovigilance because they monitor the adverse reactions to drugs and
medication. However, I found that the Sentinel system could be a great help in ensuring
that all adverse reactions to a drug were reported. Participants also described the FAERS
surveillance system as a passive methodology. One participant pointed out that the
Sentinel was better in terms of data collection and was superior to the passive FAERS
system in which compliance seemed to be optional. Participants reported that the FDA’s
Sentinel Initiative was better than the FAERS surveillance methodology. wasThe results
of this study provided information regarding the effectiveness of the FAERS and the
Sentinel Initiative. No current study compares experts’ perceptions of the FDA’s Sentinel
Initiative and the FAERS surveillance methodology.
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The second research question addressed the challenges and negative impacts of
the FDA’s Sentinel Initiative as compared with the FAERS surveillance methodology.
Both programs had challenges and negative impacts because of lack of effective and
efficient regulation to ensure that the purpose of the two systems is served. There is also
an issue of privacy in the reporting requirements. One disadvantage of the FAERS
surveillance methodology is not being able to use real-time data. One disadvantage of the
Sentinel program was the lack of responsibility in implementation and evaluation of data
collected through the Sentinel. The relativity of determining whether a certain effect was
adverse or not, it was a challenge to the effectiveness of the Sentinel surveillance policy.
Both programs had advantages and disadvantages. The FAERS surveillance methodology
was seen as a weaker methodology because it could not use real-time data and had a
small database compared to the Sentinel surveillance. However, there was lack of
accountability in the implementation and evaluation of the Sentinel Program.
It was important to determine the advantages of the Sentinel Initiative because
insights from this study could support the FDA’s efforts to improve reporting systems to
detect ADR. Robb (2012) described the advantages of the Sentinel program such as using
voluntary participants to have an active safety surveillance system. Moreover, within 2
years of its existence, the Mini-Sentinel program had 31 academic and private
organizations associated with it (Platt et al., 2012). Additionally, Forrow et al. (2012)
asserted that the Mini-Sentinel program is remarkable because it had its own
organizational structure as well as principles that regulate its operations.
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The third research question addressed the lessons learned that could enhance the
scope of the Sentinel Initiative. The study indicated that the scope of the Sentinel
Initiative could be enhanced; however, more stakeholders should be considered to make
the advantages of the policies more comprehensive and encompassing. Awareness of
these programs should also be improved so that more individuals would be able to access
the information. No study had been conducted to examine the changes that should be
made to the Sentinel Initiative for it to improve.
In this chapter, the results of the study were interpreted and the implications of the
findings were explained. The study limitations were also described and future research
recommendation was also provided. The chapter is concluded with the summary.
Interpretation of the Findings
Theme 1. The presence of FAERS and Sentinel Initiative improves the vigilance
of the public towards the adverse effects of drugs and promotes health and public safety.
Three themes emerged from the data analysis. First, the presence of FAERS and Sentinel
Initiative improves the vigilance of the public regarding the adverse effects of drugs and
promotes health and public safety. Second, the FAERS and Sentinel Initiative provide
systematic data collection for a database that uses health data to improve public health.
Third, the reporting model provides a regulatory mechanism after the drug approval
activities in order to evaluate the medicinal products.
Theme 1
Remove this blank line.
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The first finding is that the presence of FAERS and Sentinel Initiative improves
the vigilance of the public regarding the adverse effects of drugs and promotes health and
public safety. This theme was derived from the following categories: data collection,
patient’s health, regulatory mechanism, preventive measure, other stakeholders, and drug
manufacturer. In relation to the problem statement, the results indicated that both
programs had advantages and disadvantages. The participants confirmed that both
programs had the ability to make individuals vigilant about adverse effects of drugs.
However, the participants emphasized that the Sentinel Initiative was better because it
used an active system of reporting that brought immediate results. Moreover, the Sentinel
Initiative was better when it came to relative assessment of patients because the patient
might talk to an experienced health care professional, which is better than the FAERS
system in which the patient might not know where to report.
This finding confirmed existing literature about ADRs. Both the FAERS and
Sentinel Initiative improved pharmacovigilance of the public regarding the adverse
effects of drugs and promoted health and public safety. Behrman et al. (2011) stated that
the FDA Sentinel Initiative served as an additional tool for the FDA to evaluate the safety
of medical products and acted as a national resource for the FDA to take advantage of
investigating medical product performance. Additionally, the Sentinel Initiative would
become a national resource of a learning health care system. The Sentinel Initiative
enhances existing health care information to allow the FDA to perform active postmarket safety surveillance in support of the current surveillance systems had(Robb et al.,
2012). In a recent study, Sarntivijal and Abernethy (2014) found that Internet search logs

98

could also be complementary to the evaluation of FAERS reports. Henceforth, it showed
there were many methods of reporting of adverse events were evaluated by stakeholders
than just simply relying on the FAERS.
Using FAERS and the Sentinel Initiative, the FDA can scrutinize regulated
medical products nearly as fast as real time to better comprehend product safety (Robb et
al., 2012). The Sentinel Initiative aided the FDA in discovering and analyzing postmarket safety signals through signal generation, signal refinement, and signal evaluation,
which referred to the concern over an excess of irregular and negative events when
compared to what was traditionally associated with a product’s use (Robb et al., 2012).
Moreover, the Sentinel Initiative was helpful to the FDA in making regulatory decisions
(Robb et al., 2012).
Several researchers supported the use of the Sentinel Initiative through the MiniSentinel program. The Mini-Sentinel program was a pilot under the FDA Sentinel
initiative, as an effort to implement a national system that would assess the safety of
medical products. Mini-Sentinel was successful in serving as a general-purpose vaccine
safety monitoring system (Robb et al., 2012). Platt et al. (2012) found that the MiniSentinel program employed various activities such as robust surveillance of a wide range
of drugs and vaccines, as well as improving the common data model to secure additional
types of data. According to Forrow et al. (2012), the Mini-Sentinel program was
remarkable because it had its own organizational structure as well as principles that
regulated its operations. These policies and structures allowed it to influence the structure
and purpose of the Sentinel system (Forrow et al., 2012).
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In the context of the theoretical framework, this finding is consistent with theory
of preemption, which asserts that it was important to use information to make sound
judgments regarding issues or activities of national importance, such as prescription drugrelated regulations. The existence of FAERS and Sentinel Initiative provide current,
accurate, and actionable information to the FDA to ensure consumer safety, especially in
detecting uncommon cases of product exposures (Platt et al., 2009).
Due to the FAERS and Sentinel Initiative, adverse effects of drugs would be
recognized and the safety of the patients and the public would be prioritized. As a result
of the FAERS and Sentinel Initiative, the public will become more vigilant regarding the
adverse effects of drugs. Thus, the FAERS and Sentinel Initiative would improve drug
safety and public health as both systems complements each other for adverse event
reporting. The patients’ safety is enhanced due to existence of both the methods in place.
Theme 2
The second finding was that FAERS and Sentinel Initiative provided a systematic
data collection for a database that would use health data to improve public health.
Systematic data collection was included in pharmacovigilance. Pharmacovigilance
activities encompassed the collecting, exchanging, accumulating, analyzing,
interpretation, and sharing of data regarding the experiences of patients who had used a
specific drug or certain therapeutic agent (van Grootheest & Richesson, 2012). In relation
to the problem statement, study findings indicated that both programs provide systematic
data collection for a database. One of the problems in this study was to determine
whether the Sentinel Initiative was more effective as compared to FAERS. The accuracy
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of the information and the speed of obtaining information were some of the benefits that
could be derived from the Sentinel Initiative. The Sentinel surveillance methodology was
an improved way of collecting data because it was more active as it was highly imposed
and regulated. Moreover, the Sentinel Initiative could be a great help in ensuring that all
adverse reactions to a drug were reported. Moore, Furberg, Mattison, and Cohen (2016)
concluded that Sentinel surveillance methodology was a better way to collect data to
assess adverse drug events reported to the FDA.
This finding confirmed existing literature about the importance of having
systematic data collection. Researchers emphasized the importance of systematic
detection and assessment practices that could handle adverse drug effects (van Grootheest
& Richesson, 2012). Hoffman, Overstreet, and Doraiswamy (2013) stated that more than
770,000 injuries or deaths annually could be attributed to adverse events linked to drugs
already approved by the FDA. Hoffman et al. stated that approximately 28% of these
adverse events could be prevented if there was an effective computerized monitoring
system in place. Through systematic data collection, thousands of individuals could be
saved from the side effects of the drugs they used before a clinician could be subjected to
public investigation and action (van Grootheest & Richesson, 2012). FAERS had the
ability to acquire 700,000 reported adverse events annually across different therapeutic
categories, making it a powerful database (Hoffman et al., 2013).
Systematic data collection was also important for adverse drug reactions (van
Grootheest & Richesson, 2012). If an adverse drug reaction was suspected, then trials and
tests would have to be carried out to confirm or refute the suspicion. Before tests were
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carried out, careful and systematic collection of data was necessary (van Grootheest &
Richesson, 2012).
The case of banning thalidomide from the market was the result of systematic
data collection (van Grootheest & Richesson, 2012). The case propelled the FDA to start
a systematic collection of ADR reports to identify drugs that would harm individuals.
Other countries followed suit and developed new rules and regulations that organizations
needed to adhere to before releasing a new drug in the market.
In the context of the theoretical framework, this finding was consistent with the
theory of preemption, which is applied in the analysis of useddata to make market-based
decisions regarding drug safety (Gostin, 2011). The theory of preemption also involves
using data from ADRs and cases to address the damages experienced by affected
consumers (Valoir & Ghosh, 2011). Thus, systematic data collection was needed to
protect the health of the public.
The FAERS and Sentinel Initiative provided a systematic database that
professionals and experts can use to improve public health. A systematic mode of data
collection would filter what was relevant and what was not. Data collection of adverse
drug effects would help in research and prevention of ADRs in the future. Moreover,
reduction of ADRs could save thousands of lives.
Theme 3
The third finding was that the reporting model provided a regulatory mechanism
after the drug approval activities in order to evaluate the medicinal products. One of the
challenges observed in FAERS was that it was a more passive way of reporting data to

102

the FDA. In fact, reporting could be optional. Moreover, the reports sent to FAERS could
not be accessed on a real-time basis. This was a threat to the safety of the public when
important health data could not be divulged to the public in a prompt manner. Both the
FAERS and the Sentinel Initiative could be improved through responsible
implementation and evaluation.
This finding extended existing literature about the importance of having a
reporting model. The main motivation behind reporting models was to ensure public
safety and the main strategy was still population monitoring (van Grootheest &
Richesson, 2012). Reporting model was included in pharmacovigilance. Reporting
models were important because in pharmacovigilance, there was an assumption that all
therapeutic agents had a specific level of risks and these risks were not equally distributed
across the population. Thus, some groups were more likely to suffer from ADRs
compared to others (van Grootheest & Richesson, 2012). It was important to monitor and
to warn individuals of the possible side effects or adverse effects of the drug. Raine
(2012) emphasized that harmful effects from drugs should be monitored, as they could be
deadly and costly to the healthcare sector. Raine asserted that costs of adverse effects of
drugs could be greater in developing countries than in developed countries. Adverse
incidents might have a negative impact to the credibility and success of important public
health programs (Raine, 2012). In order to improve pharmacovigilance strategies, WHO
also asserted that there should be efficient and effective planning and implementing of
ADR surveillance systems (Raine, 2012).
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In the context of the theoretical framework, this finding was consistent with
theory of preemption. The theory asserts the significance of data in make sound judgment
regarding issues or activities of national importance such as public health. A reporting
model was important because it provided a regulatory mechanism after the drug approval
activities in order to evaluate the medicinal products. A reporting model should be
developed because it would help in the systematic collection of data regarding adverse
drug effects. Moreover, a specific government agency might be held accountable for the
evaluation of the effects of drugs.
Limitations of the Study
There were many limitations in this study such as researcher bias, sample size,
instrument, and data collection bias. Each limitation had an impact on this study and
every effort was done to control the effects of the limitations. One such limitation of this
study was researcher’s bias. The researcher had extensive knowledge of ADRs and
pharmacovigilance systems. In order to mitigate this bias, the researcher took data
collected during participant interviews as is and conducted member checks to ensure that
the interpretations made were consistent with the actual interpretations intended by the
participants. This limitation might have an effect on the interview guide/questions used
for data collection. Recognizing this, the interview guide/questions were written without
bias and to allow the participants to use their experiences and knowledge to answer the
questions.
Another limitation was the sample size. There was the possibility of not obtaining
enough participants. Key informants included drug company safety professionals who
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had self-reported knowledge or expertise in assessing consumer impact. However, the
study got enough participation from the sample group. The study was also limited to aim
for 20 participants with the consideration of data saturation. The limited sample size
indicated that the findings of the study might not be generalizable.
Another factor that may result to inadequate results was poorly developed
interview questions. The interview guide was developed properly to be open-ended,
specific enough to avoid confusion, and be easy to understand. To avoid this pitfall, great
care was applied in development of the interview guide.
Another limitation was the research methodology chosen. However, qualitative
design was appropriate because existing research in the area is limited. Qualitative
methodology allowed for rich description of the phenomenon.
Recommendations for Future Research
First, future researchers could extend the study to include not only the key
informants but also the consumers as well. Perception of the consumers regarding the
surveillance systems could also aid in development of policies and programs to improve
them. Moreover, perspectives of the consumer were significant since the consumers
would be the one who would experience the adverse drug effects.
Second, future researchers could also think of other factors that could influence
the effectiveness of the two programs. Most consumers were hesitant to report adverse
drug effects. This might be one of the reasons a reporting model might not be successful.

105

Third, future researchers could use a different measurement or data collection
tool. Data from the two programs could be used to determine whether health data in the
program actually improved public health. Moreover, documents could also be examined.
Lastly, future researchers could use quantitative methodology or mixed methods.
Quantitative methodology allows for collecting data from a large sample size. The size of
sample size in quantitative studies could mean that it was representative of the whole
population.
Implications of the Findings
The findings of this study had potential impact for positive change at the societal
level, organizational level, and individual level. At the individual level, individuals were
more vigilant about adverse effects of drugs and aware that they should report adverse
effects. At the organizational level, manufacturers of drugs would be informed of the
adverse effects of their drugs. Perhaps, the manufacturers could develop new drugs with
less possibility of adverse effects. At the societal level, policies about drug safety would
be modified to benefit the public.
The findings of the study were consistent with the theory of preemption. The
theory asserts the importance of using information to make sound judgment about
national issues like public healht and drug-related regulations (Deftos, 2008; Glantz &
Annas, 2008). The three findings indicated that information about adverse drug effects
were significant in ADRs research and lessening adverse drug effects and incidence of
ADRs.
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The findings of this study helped advanced research methodology in the field of
pharmacovigilance. The findings of this study revealed perceptions about effectiveness
and limitations of FAERS and the Sentinel Initiative. The findings of this study indicated
that qualitative methodology was also effective in comparing the benefits and challenges
of surveillance methodology associated with FDA’s Sentinel Initiative compared to
FAERS. The findings of the study also added to the current research base regarding
pharmacovigilance systems.
Ultimately, the results of the study increased awareness of advantages and
disadvantages of the FAERS and the Sentinel Initiative. Information from the data
provided information regarding the effectiveness of the FAERS and the Sentinel
Initiative. At this point, the Sentinel Initiative complements the FAERS system and it
does not replace FAERS system as it currently stands. The Sentinel Initiative only aims
to provide additional information on adverse drug events. The results of the study could
increase the public knowledge of the reporting systems used by the FDA to control
ADRs.
The insights from this study could support the FDA’s efforts to improve reporting
systems effectiveness to detect ADRs. The benefits and challenges of both FAERS and
the Sentinel systems found in this study could serve to be foundations for further
improvements to the programs. The presence of FAERS and Sentinel Initiative improved
the vigilance of the public towards the adverse effects of drugs. Availability of FAERS
and Sentinel Initiative also improved drug safety. FAERS and Sentinel Initiative provided
a systematic database, which included health data, that could be used to improve public
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health. As such, they must also be improved. Improvement of these programs would lead
to improvement of health and quality of life of the public because challenges of the
programs on ADR generation would be identified for ease of addressing them.
Remove this blank line.
Social Significance
This research definitely had potential to increase awareness of advantages and
disadvantages of the FAERS and the Sentinel Initiative. It was expected that the data
would provide information regarding the effectiveness of the FAERS and the Sentinel
Initiative. This study would increase the public knowledge of the reporting systems used
by the FDA to control ADRs. The lessons learned from this study could support the
FDA’s efforts to improve reporting systems effectiveness to detect ADRs. This research
would also add to the research base regarding pharmacovigilance systems. Moreover,
with the findings of the study, the benefits and challenges of both FAERS and the
Sentinel systems would determine that would serve as basis for further improvements to
the programs. Through this, health and quality of life of consumers would be improved
because the challenges of the programs on ADR generation would be identified for ease
of addressing them. As a result, safer medications would be available in the market for
consumers due to availability of huge safety data through the sentinel system which
would improve health and quality of life for patients.
The findings of this study helped in providing support for surveillance systems
such as FAERS and Sentinel Initiative. These systems monitored the adverse reactions to
drugs and medication. Monitoring the adverse reactions added to the information
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available to the public domain. Both the public and the patients benefitted from the
surveillance systems. Due to these systems, thousands of lives of people were saved.
This chapter concludes the study.
Remove this blank line.
Summary and Conclusions
Occurrence of ADRs in the U.S. have increased in the past decade. ADRs were
costly and had a negative impact on public health programs (Yadav, 2009). Moreover,
ADRs were among the leading causes of death in many countries, including the United
States. From 2004 to 2012, men and women both reported 60,000 deaths due to ADRs
(Keating & Millman, 2014). Pharmacovigilance systems such as FAERS and Sentinel
Initiative were used to detect and prevent ADRs. The purpose of this comparative case
study of the FDA Adverse Events Reporting System (FAERS) surveillance system and
the FDA's Sentinel Initiative was to determine the benefits and consequences of the
Sentinel Initiative in terms of drug consumer’s safety.
The theory of preemption assumes that it is important to use information to make
sound judgment regarding issues or activities of national importance, such as prescription
drug-related regulations, require uniform federal regulation, which cannot be provided by
states (Deftos, 2008; Glantz & Annas, 2008). Given this assumption together with the
existing literature, it was expected that there will be differences with FAERS and Sentinel
Initiative programs and that it promoted pharmacovigilance activities.
Three themes emerged from the data analysis:
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Theme 1. The presence of FAERS and Sentinel Initiative improved the
vigilance of the public towards the adverse effects of drugs and promotes
health and public safety.



Theme 2. FAERS and Sentinel Initiative provided a systematic data collection
for a database that would use health data to improve public health.



Theme 3. The reporting model provided a regulatory mechanism after the
drug approval activities in order to evaluate the medicinal products.
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Appendix A: Invitation Letter
Dear ______________:
Good day!
My name is Sonia Batra. I am a doctoral student at Walden University’s PhD Public
Health program. I am currently conducting my dissertation research on the use of the
FDA Adverse Events Reporting System (FAERS) and the Sentinel Initiative in an effort
to compare the two and determine the benefits and challenges associated to these said
programs. You are seleceted to participate in the study because you are identified as a
subject matter expert in the field of pharmacovigilance and are familiar with FDA
Adverse Event Reporting System (FAERS) and the FDA sentinel initiative. I would like
to invite you to participate in a key informant interview that will last approximately 45
minutes. The information that you can provide will be helpful in fulfilling the purpose
and significance of this study, and help improve the current state of pharmacovigilance
systems in the country.
Please be informed that your participation is protected under the ethical rules and
considerations imposed by the IRB to ensure that you are aware of your rights as
participants to this study. Please also note you will not receive any payment (thank you
gifts, compensation, or reimbursement (for travel costs, etc.)) for participating in the
research study. Should you wish to participate in this study, you may reply to signify
your interest to participate. I will then send you a copy of the informed consent, which
will need to be signed and returned to me via email or fax once you have finalized your
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decision to participate. Additionally, the informed consent may be returned to me in
person if we are having face to face interview.
Thank you very much.
Sincerely,
Sonia Batra
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Appendix B: Informed Consent
The purposes of this form are to provide you, as the potential participant of this study, with
the relevant information that may affect your decision as to whether or not to participate in
this research and to record the consent of those who agree to be involved in the study.
You are seleceted to participate in the study because you are identified as a subject matter
expert in the field of pharmacovigilance and are familiar with FDA Adverse Event
Reporting System (FAERS).
STUDY PURPOSE
The purpose of the present study of the FAERS surveillance system and the FDA's
Sentinel Initiative is to determine the benefits and consequences of the Sentinel Initiative in
terms of drug consumer safety.
DESCRIPTION OF RESEARCH STUDY
If you decide to participate, you will join a study involving telephone/face to face
interviews which will be recoded. If you say YES, then your participation will last for
approximately 45 minutes. Twenty subjects will be invited to participate in this study.
REQUIRED LANGUAGE: English
RISKS
There are minimal risks associated with participating in the study.
BENEFITS
Although there may be no direct benefits to you, the possible benefits of your
participation in the research are to identify benefits and challenges associated with
FAERS and the Sentinel Initiative to serve as basis for improvement of the programs.
NEW INFORMATION
If the researcher finds new information during the study, the information would
be shared with you and you will have an option to change your decision about
participating.
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CONFIDENTIALITY
All information obtained in this study is strictly confidential. The results of this
research study may be used in reports, presentations, and publications, but the researcher
will not identify you. In order to maintain confidentiality of your records, Sonia Batra
will use pseudonyms to replace the name or identification of each subject. Any paper
copies will be kept in a locked cabinet and electronic formats will be protected by a
password. Once the study is completed and accepted by Walden University, all digital
recordings will be deleted.
WITHDRAWL PRIVILEGE
Participation in this study is completely voluntary. It is ok for you to say no, and
you will not incur any consequences for it. Even if you say yes now, you are still free to
say no later, and withdraw from the study at any time. If you should withdraw from the
study, any digital recordings will be deleted.
Please also note you will not receive any payment (thank you gifts, compensation,
or reimbursement (for travel costs, etc.)) for participating in the research study.
VOLUNTARY CONSENT
Any questions you have concerning the research study or your participation in the study,
before or after your consent, will be answered by Sonia Batra.
This form explains the nature, demands, benefits and any risk of the project. By signing
this form, you agree knowingly to assume any risks involved. Remember, your
participation is voluntary. You may choose not to participate or to withdraw your consent
and discontinue participation at any time without penalty or loss of benefit. In signing
this consent form, you are not waiving any legal claims, rights, or remedies. A copy of
this consent form will be given (offered) to you.
Please feel free to contact me at xxx-xxx-xxxx for concerns regarding the interview or if
you have any other questions regarding the study. My email address is Xxxx@xxxx.com.
You can also contact Walden university’s Research Participant Advocate (USA number
001-612-312-1210 or email address irb@waldenu.edu) if you have any question
regarding your rights as a participant.
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Your signature below indicates that you consent to participate in the above study
___________________________
Participant's Signature

_________________________
Printed Name

____________
Date
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Appendix C. Interview Guide
Introduction
-

Greet participant. Introduce the study and its purpose

The interview is being conducted to determine the benefits and consequences of the
Sentinel Initiative in terms of drug consumer safety. This is a qualitative study focusing
on your perceptions beause you have worked closely with FAERS program and are aware
of the Sentinel Initiative.
-

Review Informed Consent

-

Provide flow of the interview

Below are the semi-structured interview questions that will be asked during the interview:
1. How does the Sentinel Initiative improve data gathering of adverse drug reactions
compared to FAERS?
a. What are the methods does the Sentinel Initiative use to improve data
gathering of adverse drug reactions compared to FAERS?
b. Who is responsible to implement and evaluate such methods?
c. What are potential challenges or risks that you perceive from these
methods?
i.

Why?

ii.

Can you tell me more about that?

d. What are potential benefits from these methods?
i.

Why?

ii.

Can you tell me more about that?

2. How does the Sentinel Initiative address underreporting of adverse drug reactions
compared to FAERS?
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a. What are the methods that the Sentinel Initiative uses to address
underreporting of adverse drug reactions compared to FAERS?
b. Who is responsible to implement and evaluate such methods?
c. What are potential challenges from these methods?
i.

Why?

ii.

Can you tell me more about that?

d. What are potential benefits from these methods?
i.

Why?

ii.

Can you tell me more about that?

3. How does the Sentinel Initiative address differential reporting of adverse drug
reactions compared to FAERS?
a. What are the methods for the Sentinel Initiative uses to address differential
reporting of adverse drug reactions compared to FAERS?
b. Who is responsible to implement and evaluate such methods?
c. What are potential challenges from these methods?
i.

Why?

ii.

Can you tell me more about that?

d. What are potential benefits from these methods?
i.

Why?

ii.

Can you tell me more about that?

4. How does the Sentinel Initiative address uneven quality of adverse drug reactions
reports compared to FAERS?
a. What does the Sentinel Initiative address uneven quality of adverse drug
reactions compared to FAERS?
b.

Who is responsible to implement and evaluate such methods?
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c. What are potential challenges from these methods?
i.

Why?

ii.

Can you tell me more about that?

d. What are potential benefits from these methods?
i.

Why?

ii.

Can you tell me more about that?

5. What are the possible strategies that limit the disadvantages/challenges of the
Sentinel Initiative in terms of its impact users?
a. Who is responsible to implement and evaluate such strategies?
b. What are potential challenges from such strategies?
c. What are potential challenges from these methods?
i.

Why?

ii.

Can you tell me more about that?

d. What are potential benefits from these methods?
i.

Why?

ii.

Can you tell me more about that?

e. Is there anything else you want to tell me about ADR surveillance?
i.

Why?

ii.

Can you tell me more about that?

f. Can you recommend another key informant who may be interested in
participating in my study?
i.

Why?

ii.

Can you tell me more about that?
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Appendix D. Emerging Codes
Code

Meaning

Data collection

FAERS and Sentinel
collect data from
patients regarding the
adverse effects of
drugs.

Use of health data

Health data is used for
the record of FDA.

Active system

The Sentinel Initiative
is an active system of
reporting.
The voluntariness of
reporting is evident in
the regulation.

Voluntary reporting

Systematic database

Reporting the adverse
drug reactions allow
having a present
systematic database.

Privacy

Privacy of the
individuals who report
adverse effects might
be at stake.

Relative assessment

There can be
differences in how a
person assesses or
evaluates the effects of
drugs.

Quotes from Participants- Supporting
Code
The availability of vast volume of data
which includes not only the drug
reaction details but also the information
such as medical history of the patient,
personal details such as age etc. also all
this information will help us derive
relevant and durable information from
the data. (Participant 17)
There are various organizations and to
be exact I believe 18 organizations that
are involved in retrieving health data.
(Participant14)
So benefits like I told you that it's an
active system they have immediate
results. (Participant 4)
FAERS is basically everything is
voluntarily done most of the time it is
more specific to particular patients.
(Participant 1)
FAERS is the FDA adverse events
reporting system. It’s a database that
contains the information on Adverse
events (AE’s) and medication errors.
(Participant 7)
I really see here is the privacy issue.
The HIPAA compliance. I don’t know if
the patients would like to share their
information to a third party. (Participant
6)
With the FAERS system addressing
adverse differential FAERS is
dependent on whether the patient really
calls FDA or health care company and
that one is limited. Whereas with
Sentinel the patient may be either
talking to healthcare profession that I
had reaction with drug and it might get
reported much more better than the
FAERS system where the patient might
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Code

Meaning

Unexpected adverse

The unexpected
adverse effects of
drugs should be
reported in order to be
prevented.
The adverse effects of
drugs pose threats to
public health.

effects
Threats to public
health
Health safety

Patient-centeredness

Coincidental
occurrences

Risk evaluation

Health safety of
patients can be
achieved if drugs are
safe.

Quotes from Participants- Supporting
Code
even not know where to report.
(Participant 8)
There would be more clinical
information available regarding the
adverse effect and what was happening
so that would be one major benefit.
(Participant 12)
I say society it means all the players
who are responsible for managing
healthcare in the system. (Participant 2)

The potential benefits of the patients
ultimately the FDA was created to
benefit the patients and consumers and
the larger population will be benefited
by this and more genotyping &
genomics data. (Participant 2)
FAERS and Sentinel
I think it’s mostly patients safety, they
Initiative are focused
are having a lot of information sharing it
on the welfare of
they are able to share it, they are
patients.
compiling they are getting a great deal
more info on all these products
hopefully to be used for a patient safety.
(Participant 20)
Coincidental
I can confirm it if you like all the
occurrences on patients adverse reactions that happened whether
that do not have direct it was on doctors clinic or it happened
correlation to the drugs anywhere else in the hospital only 6might be mistaken as
10% were reported since the institution
adverse drug effects.
established FAERS whereas the sentinel
program because it is not asking you
report anything it is asking you to just
keep your data in a particular format
(Participant 2)
The risks on drugs will I think the challenges are that you know
properly be assessed if with a lot of data you also comes with it
there is a proper
is noise and you know the quality of
reporting model.
data and probably you can have where
signals will get lost and then you have
different interpretations of signals of
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Code

Meaning

Quotes from Participants- Supporting
Code
what is actually a risk and what is I
think it gets a little bit murky with that
large amount of data (Participant).

Reporting model

The reporting model of
how adverse drug
effects are recorded
should be systematic.

Post-drug approval

Post-drug approval
activities must be
evaluated to ensure the
safety of the public.

It doesn’t seem that they have a separate
method they can use to overcome under
reporting of worst events so if the data
is not there they can obtain any
additional information. (Participant 5)
So basically they use all these query
methods so that they can query these
large database to determine to get the
desired results of what are on what
features are they looking for and what
kind of problems they want to solve or
especially what drug they want to
improve. (Participant 4)
Evaluation is done principally by FDA
and they will be the one who will
analyze the data and gather critical
information out of this. (Participant 18)
So here again I think the agency has the
ultimate responsibility when it comes to
reporting though in general it is on …
it’s on the health care professionals and
consumers. (Participant 20)

activities

Evaluation of
products
Responsibility

Accountability

Preventive action

Alerting the public

The proper evaluation
of products should be
the priority in order to
ensure health safety.
There should be a
government agency
that regulates drugs in
order to monitor
responsibility on the
safety of drugs.
There should be a
government agency
that regulates drugs in
order to monitor
accountability on the
safety of drugs.
The reporting model is
a form of preventive
action to ensure that
future similar incidents
will be prevented.
The public has the
right to know on the
possible adverse drug

Again the FDA, the stakeholders are
solely responsible for implementing and
evaluating these methods. (Participant
17)
I think there are may be 18
organizations collecting this data help
data warehousing and ensure companies
like that have access to vast of data and
vast of health data. (Participant 13)
The potential challenges which I am
looking upon in this under reporting of
adverse from these methods is to instill
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Code

Meaning
effects based on the
experience of others.

Evidence-based

Vigilance

The reporting of
adverse drug effects by
the patients will allow
evidence-based
conclusions.
Vigilance in the
pharmaceutical
industry must be
improved.

Accessibility

The records and data
collected should be
made accessible to the
public.

Inclusive

A more inclusive
system should be
created so that the
development will go
beyond research
purposes.

Discovery of new

New risks on the
adverse drug effects
will be prevented.

risks

Other stakeholders

A more inclusive
progress in the field of
pharmacovigilance is
possible if there are
more stakeholders.

Quotes from Participants- Supporting
Code
a sense of security amongst the patients
and we have to educate them that their
personal data is only used for medicinal
and research purposes. (Participant 17)
Doctor must have prescribed something
and there must be some evidence and
records they don’t have to wait for
many years. (Participant 19)
I mean all the stake holders that are
involved should be responsible whether
be the manufacturers or the distributors
or the FDA or the healthcare
professionals or even the patient.
(Participant 16)
Information is generally documented
within the healthcare providers database
it’s more readily accessible to FDA to
perform to better evaluate the data.
(Participant 16)
To obtain extensive stakeholders and
partners to participate in this imitative
there will have to some kind of method
to educate consumer for this work so
that they may be able to share their
health care info to the database.
(Participant 5)
That it can eliminate under reporting to
extent but it will be still be there
because the access to data is small and I
think they are also working on it once
data bases are linked and they have
access to those databases then they will
have better analysis to problems of
adverse drug reactions. (Participant 4)
Consumer may not allow releasing their
health care info and they need to
increase their stakeholders if they want
to expand and implement all over the
country. (Participant 5)
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Code

Meaning

Drug safety

Drug safety should be
prioritized in ensuring
that there are proper
reportorial
mechanisms.
Healthcare
professionals will
improve their
performance if the
drugs are properly
regulated.
Disease occurrence can
be lessened if there is
proper regulation of
drugs available in the
market.

Opportunity to
improve healthcare
professionals

Disease occurrence

Quotes from Participants- Supporting
Code
It will help derive the FDA and to
evaluate about a drug and take some
safety measures about a drug.
(Participant 17)
So the challenge again would be the
lack of partnership, they have to
increase their partnership to all
physicians, pharmacies in order to
expand their data base. (Participant 5)
There are some other diseases and other
things that I have and if I am going to
take this medication it going to have an
impact on me. (Participant 19)
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Appendix E. Emerging Themes
Themes

Total No. of
Responses

Theme 1. The presence of FAERS 52
and Sentinel Initiative improves
the vigilance of the public
towards the adverse effects of
drugs and promotes health and
public safety.

Associated Codes and Categories
Patient’s Health (Total: 15)
Unexpected adverse effects (4)
Threats to public health (4)
Patient-centeredness (3)
Health safety (2)
Coincidental occurrences (2)
Preventive Measure (Total: 12)
Vigilance (4)
Preventive action (3)
Alerting the public (3)
Evidence-based (2)
Drug Manufacture (Total: 12)
Drug safety (6)
Opportunity to improve healthcare
(3) professionals
Disease occurrence (3)
Other Stakeholders (Total: 13)
Other stakeholders (5)
Accessibility (3)
Inclusive (3)
Discovery of new risks (2)

Theme 2. FAERS and Sentinel
Initiative provide a systematic
data collection for a database that
would use health data to improve
public health.

Theme 3. The reporting model
provides a regulatory mechanism
after the drug approval activities
in order to evaluate the medicinal

28

22

Data Collection (Total: 28)
Systematic database (7)
Privacy (4)
Voluntary reporting (4)
Data collection (4)
Active system (4)
Use of health data (3)
Relative assessment (2)
Regulatory Mechanism (Total: 22)
Accountability (6)
Reporting model (4)
Post-drug approval activities (4)
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products.

Risk evaluation (3)
Evaluation of products (3)
Responsibility (2)

